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Abstract 
Approximately 3% of the general population is affected by epilepsy during lifetime, 
making epilepsy one of the most common neurological diseases. Genetic generalized 
epilepsies (GGE) are the most common of genetic epilepsies and account for 20-30% 
of all epilepsies. GGE is subdivided into genetically determined subgroups with 
gradual transition, including genetic absence epilepsies (GAE), juvenile myoclonic 
epilepsy (JME), and epilepsy with generalized tonic-clonic seizures (EGTCS). In spite 
of a high heritability rate of 80% and a predominant genetic etiology, the genetic 
factors predisposing to GGE are still mostly unknown. In the present study, we 
carried out association studies to investigate whether genomic microdeletions and 
common susceptibility variants increase risk for GGE. 
To test the common disease/common variant hypothesis, genome-wide association 
studies (GWAS) were performed in several GGE cohorts using case-control and 
family-based study designs. For analysis, all patients were either pooled or stratified 
according to the subgroup they belong to in order to detect common or subgroup-
specific risk factors, respectively. The GWAS comprised a case-control cohort of 
1,523 European GGE patients and 2,454 German controls and a sample cohort of 566 
European parent-offspring trios. Meta-GWAS analyses revealed significant 
association (P < 5.0 × 10-8) with GGE at 2p16.1 (rs35577149, meta-analysis P = 1.65 
× 10-8, OR[C] = 0.78, 95% CI 0.71 – 0.86). Significant association with JME was 
detected at 1q43 (rs12059546, meta-analysis P = 2.27 × 10-8, OR[G] = 1.53, 95% CI 
1.33 – 1.78). Suggestive evidence for association (P < 1.0 × 10-5) was found for GGE 
at 8q12.2 (rs6999304, meta-analysis P= 1.77 × 10-6, OR[G] = 1.33, 95% CI 1.17 - 
1.51) and for GAE at 2q22.3 (rs75917352, meta-analysis P = 1.41 × 10-7, OR[T] = 
0.67, 95% CI 0.58 – 0.79). The associated regions harbor high-ranking candidate 
genes: CHRM3 at 1q43, VRK2 at 2p16.1, and ZEB2 at 2q22.3. Further replication 
efforts are necessary to elucidate whether these positional candidate genes 
contribute to the heritability of the common GGE syndromes. 
Exploring the rare variant/common disease hypothesis, we investigated the impact 
of six recurrent microdeletions on the genetic risk of GGE at the genomic hotspot 
regions 1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p13.11, and 22q11.2, which had been 
Abstract 
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implicated as rare genetic risk factors in a wide range of neurodevelopmental 
disorders. Recurrent microdeletions were assessed in 1,497 European GGE patients, 
5,374 controls, and 566 GGE trios using high-resolution SNP microarrays. 
Considering all six microdeletion hot spots together, we found a significant excess of 
these microdeletions in 2,563 GGE patients versus 5,940 controls (P < 2.20 × 10−16, 
OR = 7.65, 95% CI 4.59 – 13.18). Individually, significant associations with GGE were 
observed for the microdeletions at 15q11.2 (P = 1.12 × 10−4, OR = 3.59, 95% CI 1.80 
– 7.25), 15q13.3 (P = 5.48× 10−9) and 16p13.11 (P = 4.42× 10−6, OR = 17.39, 95% CI 
3.86 – 159.88). 
In a candidate-gene approach, we tested whether exon-disrupting/removing 
microdeletions in the genes encoding NRXN1 and RBFOX1 confer susceptibility for 
GGE. We found a significant association with GGE at both loci (NRXN1: P = 0.0049; 
RBFOX1: P = 0.0083). However, high phenotypic variability and incomplete 
penetrance, resulting in apparently imperfect segregation, indicate that partial 
NRXN1 and RBFOX1 deletions represent susceptibility factors rather than highly 
penetrant mutations. 
The present study substantiates a role of both genomic microdeletions and common 
susceptibility variants in the genetic predisposition of common GGE syndromes. We 
strengthened the statistical evidence for associations of genetic variants at 1q43, 
2p16.1, and 2q23.2 with GGE syndromes and identified a novel susceptibility locus 
at 8q12.2. Although individually rare, the associations of all microdeletions at 
15q11.2, 15q13.3, 16p13.3, NRXN1, and RBFOX1 taken together contribute 
significantly to the genetic variance of GGE. 
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Zusammenfassung 
Etwa 3% der allgemeinen Bevölkerung ist zu Lebzeiten von Epilepsie betroffen. 
Somit ist Epilepsie eine der häufigsten neurologischen Erkrankungen. Genetische 
generalisierte Epilepsien (GGE) sind die häufigsten genetisch bedingten Epilepsien 
und verantwortlich für 20-30% aller Epilepsien. Die GGE lassen sich in Subgruppen 
mit fließenden Übergängen im Phänotyp unterteilen. Zu diesen zählen die 
genetische Absence-Epilepsie (GAE), die juvenile myoklonische Epilepsie (JME) und 
die Epilepsie mit generalisierten tonisch-klonischen Anfällen (EGTCS). Trotz einer 
hohen Erblichkeit von 80% und einer überwiegend genetischen Ätiologie, sind die 
genetischen Faktoren zur Entstehung von GGE immer noch weitgehend unbekannt. 
In der vorliegenden Studie führten wir Assoziationsstudien durch, um zu 
untersuchen, ob genomische Mikrodeletionen und häufige Suszeptibilitäts-
Varianten das Risiko für GGE erhöhen. 
Um die „common disease/common variant“-Hypothese zu testen, wurden 
genomweite Assoziationsstudien (GWAS) in mehreren GGE-Kohorten unter 
Verwendung von fall-kontroll- und familien-basierten Studiendesigns durchgeführt. 
Für die Analyse wurden die Patienten sowohl alle zusammen als auch nach der 
Zugehörigkeit zur jeweiligen Untergruppe separat betrachtet, um gemeinsame oder 
untergruppen-spezifische Risikofaktoren zu erkennen. Die GWAS umfasste eine Fall-
Kontroll-Kohorte mit 1.523 GGE-Patienten europäischen Ursprungs und 2.454 
deutschen Kontrollen, sowie einer Probenkohorte aus 566 europäischen Eltern-
Kind-Trios. Meta-GWAS-Analysen ergaben signifikante Assoziation (p <5,0 x 10-8) 
mit GGE auf 2p16.1 (rs35577149, Meta-Analyse P = 1,65 × 10-8, oder [C] = 0,78, 
95% CI von 0,71 bis 0,86). Signifikante Assoziation mit JME wurde auf 1q43 
nachgewiesen (rs12059546, Meta-Analyse P = 2,27 × 10-8, OR [G] = 1,53, 95% CI 
1,33 bis 1,78). Suggestive Assoziation (P <1,0 × 10-5) mit GGE wurde auf 8q12.2 
gefunden (rs6999304, Meta-Analyse P = 1,77 × 10-6, oder [G] = 1,33, 95% CI 1,17 bis 
1,51), sowie für GAE auf 2q22.3 (rs75917352, Meta-Analyse P = 1,41 × 10-7, oder 
[T] = 0,67, 95% CI 0,58 bis 0,79). Die damit verbundenen Regionen beherbergen 
hochrangige Kandidatengene: CHRM3 auf 1q43, VRK2 auf 2p16.1 und ZEB2 auf 
2q22.3. Weitere Replikationsstudien sind notwendig, um herauszufinden, ob diese 
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positionellen Kandidatengene zur Erblichkeit von häufigen GGE-Syndromen 
beitragen. 
Zur Erforschung der „common disease/rare variant“-Hypothese untersuchten wir 
den Einfluss von sechs rekurrenten Mikrodeletionen auf das genetische Risiko von 
GGE. Diese treten in genomischen „Hotspot“-Regionen bei 1q21.1, 15q11.2, 15q13.3, 
16p11.2, 16p13.11 und 22q11.2 auf und waren zuvor als seltene genetische 
Risikofaktoren in einer Vielzahl von neurologischen Erkrankungen erkannt worden. 
Die Untersuchung der rekurrenten Mikrodeletionen erfolgte primär mit 
hochauflösenden SNP-Mikroarrays in 1.497 europäischen GGE-Patienten, 5.374 
Kontrollen und 566 GGE-Trios. Wenn alle sechs Mikrodeletions-Hotspots zusammen 
betrachtet wurden, zeigte sich eine signifikante Anhäufung dieser Mikrodeletionen 
in einer erweiterten Stichprobe von 2.563 GGE-Patienten im Vergleich zu 5.940 
Kontrollen (P <2.20 × 10-16, OR = 7.65, 95% CI 4,59 bis 13,18). Einzeln betrachtet 
wurden signifikante Assoziationen mit GGE für die Mikrodeletionen auf 15q11.2 (P = 
1.12 × 10−4, OR = 3.59, 95% CI 1.80 – 7.25), 15q13.3 (P = 5.48× 10−9) und 16p13.11 
(P = 4.42× 10−6, OR = 17.39, 95% CI 3.86 – 159.88) gefunden. 
In einem Kandidaten-Gen-Ansatz haben wir getestet, ob Multi-Exon-Deletionen in 
den Genen NRXN1 und RBFOX1 zur Suszeptibilität von GGE beitragen. An beiden 
Loci (NRXN1: P = 0,0049; RBFOX1: P = 0,0083) fanden wir eine signifikante 
Assoziation entsprechender Mikrodeletionen mit GGE. Allerdings deuten die 
beobachtete hohe phänotypische Variabilität und unvollständige Penetranz und die 
daraus resultierende unvollkommene Segregation in den betroffenen Familien 
darauf hin, dass partielle Deletionen von NRXN1 und RBFOX1 eher als 
Suszeptibilitäts-Faktoren denn als hoch-penetrante Mutationen zu betrachten sind. 
Die vorliegende Studie belegt, dass sowohl genomische Mikrodeletionen als auch 
häufige Suszeptibilitätsvarianten eine wichtige Rolle für die genetische 
Prädisposition von häufigen GGE-Syndromen spielen. So gelang es, die statistische 
Evidenz für Assoziationen von genetischen Varianten auf 1q43, 2p16.1 und 2q23.2 
mit GGE-Syndromen zu erhöhen und einen neuen Suszeptibilitätslokus auf 8q12.2 
zu identifizieren. Ferner zeigte sich, dass seltene Mikrodeletionen auf 15q11.2, 
15q13.3 und 16p13.3 sowie an den Genloci NRXN1 und RBFOX1 in ihrer Gesamtheit 
erheblich zur genetischen Varianz von GGE beitragen. 
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1 
1 Introduction 
1.1 Introduction to Epilepsy 
Epilepsy is a remediless disorder of the brain, defined by the occurrence of at least 
one unprovoked epileptic seizure. These seizures appear as symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain (Fisher et al., 
2005). Approximately 3% of the general population are affected by an epilepsy 
during lifetime, making epilepsy one of the most common neurological diseases 
(Hauser et al., 1993; Freitag et al., 2001). The clinical condition may be seriously 
troubling for the patient and for his social environment, and result in increased 
morbidity and premature mortality (Duncan et al., 2006). Up to 50% of epilepsy 
patients show a comorbidity of other cognitive, behavioral, psychiatric and 
neurologic disorders, and even sudden death (Tellez-Zenteno et al., 2007; Jensen, 
2011; Kanner, 2013). 
A genetic background of epilepsy is unquestioned and has been represented in twin 
and family studies (Berkovic et al., 1998; Callenbach et al., 1998; Bianchi et al., 2003; 
Johnson et al., 2003; Kjeldsen et al., 2003). Although 50% of epilepsies are 
genetically determined, monogenic epilepsies account only for 1-2% of all human 
epilepsies (Pandolfo, 2011). A number of causative genes have been identified for 
those forms with a clear family history and simple inheritance, many of them 
encoding for ion channels or other components of neuronal signaling (Meisler et al., 
2001; Reid et al., 2009; Yalçın, 2012a). Despite these distinct findings, variable 
penetrance and expressivity could be shown for known epileptogenic mutations in 
animal models, depending on the genetic background (Bergren et al., 2005; Yu et al., 
2006; Tan et al., 2008). 
For sporadic epilepsies, a complex genetic component is obvious and a population-
specific contribution most likely, although difficult to verify (Greenberg et al., 2000; 
Cavalleri et al., 2007; Guo et al., 2012). Nonetheless, recent genome-wide association 
studies (GWAS) were able to successfully identify susceptibility loci for epilepsy 
(EPICURE Consortium et al., 2012a; Guo et al., 2012). Computational simulations 
indicate that even small simultaneous changes in several ion channel genes may 
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have a severe effect, modeling a complex genetic background for common epilepsies 
(Thomas et al., 2009). 
A still increasing number of pathogenic genes, copy number variants and gene 
regulatory elements have been discovered that are not directly or not at all 
connected with ion channels or neuronal signaling (Gurnett and Hedera, 2007). 
Therefore, the list of potential candidates for epilepsies is extraordinary large. 
Despite technical innovations and their remarkable impact on epilepsy research in 
the past 3 to 15 years (Rees, 2010; Poduri and Lowenstein, 2011a; Hildebrand et al., 
2013; Vorstman and Ophoff, 2013), the genetic factors predisposing to epilepsy 
remain mostly elusive (Helbig and Lowenstein, 2013). 
The identification of additional genes influencing the risk for epilepsies has large 
potential for clinical applications. Diagnostic and predictive testing based on genetic 
information may help patients to make informed decisions about managing their 
health care, despite a primary benefit to pharmacogenomics (Ottman et al., 2010). 
1.2 Classification of genetic generalized epilepsy (GGE) syndromes 
The classification of epileptic syndromes is an outstanding challenge that has been 
faced for almost 50 years (Gastaut, 1964, 1969; ILAE, 1981, 1985, 1989). 
Progressions in the understanding of epilepsies induced several revisions and 
updates to the traditional classification (Engel, 2001, 2006; Nordli, 2005; Capovilla 
et al., 2009), and have now outdated former concepts. In 2010, the International 
League Against Epilepsy (ILAE) Classification Commission introduced a new 
proposal for new terms and concepts to describe seizures and epilepsies (Berg et al., 
2010). The terms idiopathic, symptomatic and cryptogenic have been replaced by 
the terms genetic, structural/metabolic and unknown (Berg et al., 2010). In contrast 
to the structural/metabolic (former symptomatic) epilepsies, idiopathic or genetic 
epilepsies occur in the absence of neurological deficits, intellectual disability, or 
brain lesions and have no known or suspected external cause, and genetic factors 
are implicated (Figure 1-1) (Berkovic et al., 2006; Helbig et al., 2008). 
Generalized epilepsies are divided into subgroups by seizure type. Those groups are 
represented by seizures with tonic and/or clonic manifestations (tonic-clonic 
seizures, clonic seizures, and tonic seizures), absences (typical absences, atypical 
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absences, and myoclonic absences), myoclonic seizure types (myoclonic seizures, 
myoclonic astatic seizures, and eyelid myoclonia), epileptic spasms and atonic 
seizures (Classification from Engel, 2006. See Suppl. 6-1 for a more detailed 
overview, including non-generalized forms). These groups may be further divided 
by age of onset and additional cofactors. Four of these subtypes account for more 
than 90% of GGEs: Childhood absence epilepsy (CAE), juvenile absence epilepsy 
(JAE), juvenile myoclonic epilepsy (JME) and epilepsy with generalized tonic-clonic 
seizures (EGTCS) (Mullins et al., 2007). Those subgroups are often easy to 
distinguish by age of onset (CAE: 4-8 years, avg. 7.5 years; JAE: 9-13 years, avg. 13.3 
years; JME: 12-18 years, avg. 14.6 years; EGTCS: 6-28 years, peak at 17.1 years), 
electroencephalography (EEG) patterns and by type and occurrence of seizures 
(Janz, 1997; Nordli, 2005). There has been evidence that those four generalized 
epilepsy syndromes are closely related to each other, showing similar EEG patterns 
and excitability in neuronal networks (Moeller et al., 2011; Zambrelli and Canevini, 
2011), analogous to family studies suggesting a close genetic relation between CAE 
and JAE (Marini et al., 2004). Despite these findings and a high rate for remission of 
65% until adolescence in CAE, 15-18% of all CAE patients develop JME, 
demonstrating some connection between the syndromes (Wirrell et al., 1996; 
 
Figure 1-1 | Biological spectrum of epilepsy (Adapted from Berkovic et al., 2006) 
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Martínez-Juárez et al., 2006). However, phenotypic heterogeneity can be observed 
within families, that are affected by differing seizure types (Kinirons et al., 2008). 
GTCS alone is present in about 50% of the cases, while about 70% of patients with 
other syndromes experience GTCS at least once in their lifetime (Janz, 1997; Mullins 
et al., 2007). Several linkage studies support the hypothesis, that interactions and 
different combinations of common disease loci for GGE are responsible for the 
spectrum of heterogeneous phenotypes (Figure 1-2) (Sander et al., 2000; Durner et 
al., 2001; Hempelmann et al., 2006; EPICURE Consortium et al., 2012b). 
1.3 Genetic factors of GGE syndromes 
The incidence of GGEs is about 20-30%, depending on the tested population (Berg et 
al., 1999; Freitag et al., 2001; Jallon et al., 2001). About 4-8% of GGE patients have a 
family history of epilepsy, with most affected relatives having GGE as well 
(Callenbach et al., 1998; Bianchi et al., 2003). 
Furthermore, offspring of GGE patients is reported to be three times more likely 
affected than expected by population incidence rates, with a recurrence risk of 4-
10% in siblings (Ottman et al., 1989; Bianchi et al., 2003). Several twin studies 
showed high concordance rates of generalized epilepsy phenotypes in monozygotic 
 
Figure 1-2 | Overlap of the complex phenotypes of most common genetic generalized epilepsies (modified 
from Janz et al., 1997; Crunelli and Leresche, 2002). 
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twins (concordance rate of 0.65-0.82 in MZ and 0.12-0.26 in DZ), suggesting the 
strong influence of syndrome-specific susceptibility genes in the etiology of epilepsy 
(Berkovic et al., 1998; Kjeldsen et al., 2003). On the contrary, extensive family 
studies found high phenotype variability within pedigrees (Scheffer and Berkovic, 
1997; Ottman et al., 1998). Concordance rates in families with myoclonic and/or 
absence seizure of 58-65% with seizure types led to the conclusion, that some genes 
confer susceptibility to only one specific GGE syndrome, while others contribute to a 
broader range of phenotypes (Winawer et al., 2002, 2005). 
To date, the best characterized genes in GGE are EFHC1 (myoclonin-1), GABRA1 
(gamma-aminobutyric acid (GABA) A receptor, alpha 1 subunit), GABRG2 (gamma-
aminobutyric acid (GABA) A receptor, gamma 2 subunit), CACNA1A (calcium 
channel, voltage-dependent, P/Q type, alpha 1A subunit), CACNB4 (calcium channel, 
voltage-dependent, beta 4 subunit) and SLC2A1 (solute carrier family 2 (facilitated 
glucose transporter), member 1) (Pandolfo, 2011). 
EFHC1 encodes for a calcium binding protein and is supposed to be involved in 
regulating cell division and neuronal migration during cortical development (de Nijs 
et al., 2009; Léon et al., 2010) and EFHC1 mutations were found co-segregating in 
unrelated families with JME (Suzuki et al., 2004). Disruption of EFHC1 causes subtle 
malformations occurring in cortical and subcortical development associated with 
JME (de Nijs et al., 2009, 2012; Wong, 2010). 
GABAA receptor function was expected to play a role in epileptogenesis for a long 
time, because of its key function as in inhibitory synaptic neurotransmission (Olsen 
et al., 1999). The first genetic evidence was a GBARG2 mutation in a family with 
generalized epilepsy with febrile seizures (FS) (Baulac et al., 2001). Additional 
GBARG2 mutations were later reported in patients with CAE (Wallace et al., 2001; 
Crunelli and Leresche, 2002), followed by a report of a GABRA1 mutation in family 
members with JME (Cossette et al., 2002). Both mutations of GABRA1 and GBARG2 
has been found in families with different phenotypes including CAE, CAE with FS and 
generalized epilepsy with febrile seizures plus (GEFS+) (Crunelli and Leresche, 
2002; Lachance-Touchette et al., 2011). Other GABAA receptor subunit mutations in 
GABRB3 and GABRD have been identified in diverging epilepsy phenotypes as well 
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(Macdonald et al., 2010), highlighting the strong impact of the GABAA receptor genes 
in epileptogenesis. 
Genes of the voltage-dependent calcium channel complex proteins were identified in 
GGE syndromes. The effect of CACNB4 mutations were described in mice and in 
families with heterogeneous GGE phenotypes, respectively CAE with JME and GTCS, 
JME with GTCS, and ataxia (Escayg et al., 2000). Similarly, mutations in CACNA1A 
were found in patients with CAE and ataxia (Jouvenceau et al., 2001). 
Several other mutations in ion channel genes were described for GGE subtypes that 
are not included in this study, appreciable mutations in KCNQ2 and KCNQ3 in benign 
familial neonatal convulsions and SCN1A, SCN2A, SCN1B mutations in GEFS+ and 
Dravet syndrome (Claes et al., 2001; Gardiner, 2005). 
An important non-ion channel gene to the etiology of GGE is SLC2A1, encoding the 
GLUT1 glucose transporter. Mutations altering gene function have been detected in 
patients with early-onset absence epilepsy (Suls et al., 2009). Again, SLC2A1 shows a 
phenotypic spectrum besides GGE, including epileptic encephalopathy, GTCS as well 
as absence, myoclonic and atonic seizures associated with generalized spike-wave 
on EEG (Harkin et al., 2007; Mullen et al., 2011). 
While the dogma of epilepsy in general as a channelopathy is put aside, newly 
discovered genes illustrate the importance of unstudied pathways in the etiology of 
epilepsy (Turnbull et al., 2005; Greenberg and Subaran, 2011; Poduri and 
Lowenstein, 2011b). As part of the GABA synthesis pathway, the genome-coded 
mitochondrial enzyme ME2 is strongly suggested to be predisposing to GGE (Pal et 
al., 2003). Accordingly, association with the BRD2 gene locus could be identified in 
patients with JME, although gene function is yet unknown (Pal et al., 2003). Other 
reports introduce other novel risk factors, for instance ARX to absence seizures and 
GTCS (Marsh et al., 2009), STXBP1 to genetic subtypes of Ohtahara syndrome (Saitsu 
et al., 2008), PNKP to a previously unknown syndrome (microcephaly, early-onset, 
intractable seizures and developmental delay, MCSZ) (Shen et al., 2010) and PCDH19 
to epilepsy and mental retardation limited to females (Dibbens et al., 2008). 
In most cases the relation between mutation and epilepsy phenotype is unclear, 
hindered by genetic heterogeneity with variable expressivity, emphasizing the 
Introduction | 1 
7 
importance of genetic background to specific epilepsy phenotypes (Reid et al., 
2009). Hence most epilepsy patients have no affected relatives, a genetically 
complex etiology for the majority of all epilepsies is most likely, with multiple genes 
of moderate effect contributing to disease risk and clinical outcome (Ottman, 2005; 
Johnson, 2011). This assumption favors the model of a polygenic and multifactorial 
etiology of common epilepsy syndromes, with multiple genes and environmental 
factors involved (Figure 1-3). 
Genome wide linkage and association studies have reported a number of different 
loci for GGEs. Early linkage mapping studies found evidence for susceptibility loci on 
chromosomes 2q36, 6p21, 14q23 and 20q13 (Sander, 1996; Sander et al., 2000). 
Association was found both in CACNA1A and CACNA1H, supporting the findings in 
Mendelian epilepsies (Chioza et al., 2001; Vitko et al., 2005). A recently published 
linkage study identified a novel risk loci at 5q34, close to several genes of the GABAA 
receptor (GABRB2, GABRA6, GABRA1, GABRG2) (EPICURE Consortium et al., 2012b), 
and consenting evidence of prior reported susceptibility loci at 2q34 (Ratnapriya et 
 
Figure 1-3 | Multifactorial-polygenic model of disease. Liability, an immeasurable quantitative 
trait, is normally distributed in the population. Individuals with liability above a threshold value are 
affected. With epilepsy, the threshold could be conceived of as a seizure threshold. Modified from 
Ottman et al., 2005. 
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al., 2010) and 13q31.3 (Tauer et al., 2005; Hempelmann et al., 2006). Replication in 
independent families/cohorts usually failed and no ‘common epilepsy genes’ could 
be identified (Mulley et al., 2005). 
Association studies of candidate genes are based on the ‘common disease, common 
variant’ model (CDCV), assuming that common variations with moderate effect 
contribute to disease risk. The validity of this model was disputed after more than 
50 studies without consisting results (Tan et al., 2004). In contrast, the ‘common 
disease, rare variant’ (CDRV) model, with rare variants with strong effects on 
disease outcome, was considered to be more fitting to complex epilepsy (Mulley et 
al., 2005). Besides, inadequate study designs might have contributed to the lack of 
success in epilepsy research (Kasperaviciūte et al., 2010; Tan and Berkovic, 2010; 
Heinzen et al., 2012). Nonetheless, the identification of indisputable genetic risk 
factors warrant further association studies (Pandolfo, 2011; Hildebrand et al., 2013). 
Association studies in Chinese population identified variants in CACNA1H for CAE 
(Liang et al., 2007) as well as CAMSAP1L1 and GRIK2 for general epilepsy (Guo et al., 
2012). The to date largest GWAS in European population has found significant 
association in Linkage Disequilibrium (LD) blocks, including VRK2 and PNPO as 
potent candidate genes, as well as genetic susceptibility in SCN1A for GGE in general, 
as well as susceptibility alleles in ZEB2 for GAE, CHRM3 for JME (EPICURE 
Consortium et al., 2012a). 
In the same way, gene-gene interactions and modifiers are important factors for 
epileptogenesis. As an example, combinations of mild phenotype alleles can result in 
a severe clinical phenotype (Reid et al., 2009). Mouse models have demonstrated the 
effect of gene-gene interactions (Kearney et al., 2006), as well as the impact of 
protective and modifier variants (Kim et al., 2001; Glasscock et al., 2007; Martin et 
al., 2007c; Jorge et al., 2011). 
1.4 Structural genomic variations in human disease 
Although pathogenic structural genomic variations are known for quite some time 
(given the 15q11-13 deletion and duplication syndromes as a prominent example) 
(Butler et al., 1986; Bundey et al., 1994), investigation was often difficult and limited 
to large structural variations with severe effects. Due to technological advances the 
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understanding of this variations, especially duplications and deletions that are 
collectively called Copy Number Variations (CNVs), has made huge progress. First 
databases were established in 2004 (Iafrate et al., 2004), soon followed by a better 
understanding of the underlying genetic framework of CNVs (Sebat et al., 2004; 
Tuzun et al., 2005). Despite as assumed before, further mapping approaches showed 
that CNVs are not rare events, but are far more common than expected (Redon et al., 
2006). CNVs contribute more to genomic diversity than any other genomic variation 
previously discovered (Redon et al., 2006; Korbel et al., 2007; Stranger et al., 2007). 
Great efforts have been made to reveal the mechanisms underlying genomic 
rearrangements (Sebat et al., 2004; Tuzun et al., 2005), identifying three major 
principles that may cause CNVs (Gu et al., 2008). Regions with low-copy repeats 
(LCRs) can mediate non-allelic homologous recombination (NAHR) events. NAHRs 
mostly account for recurrent CNVs, which share the same breakpoint positions and 
sizes, resulting in almost identical events in multiple individuals. Non-recurrent 
CNVs, that may be stimulated by LCRs, do not share the same breakpoints or size, 
but still may show some overlap or redundant core regions in different samples. In 
rare cases, no-recurrent NAHRs may be caused as well by highly homologous 
repetitive sequences like Alu or LINE elements (Gu et al., 2008; Slavotinek, 2008). 
Non-recurrent CNVs may as well be caused by non-homologous end-joining (NHEJ), 
which occurs during DNA double-strand break repair. NHEJ may lead to 
modification of broken DNA strands to allow for ligation of the breakpoints, that 
may add or delete several base pairs (Gu et al., 2008). 
Other non-recurrent events may be mediated by replication Fork Stalling and 
Template Switching (FoSTeS) (Lee et al., 2007; Gu et al., 2008). During DNA 
replication, the replication fork may pause, the lagging strand disconnecting from 
the template and annealing to another replication fork due to microhomology. The 
replication would then continue at the new position, creating a duplication by 
switching to an upstream replication fork, or a deletion by switching to a 
downstream position. The orientation of the replication fork may cause inversions 
in addition any may occur several times in a row. 
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Large CNVs may encompass a high number of genes, without any apparent 
phenotype (Iafrate et al., 2004; Sebat et al., 2004; Redon et al., 2006). On the 
contrary, CNVs may affect gene functions in different ways (Cook and Scherer, 
2008), commonly considered as changes in gene dosage or expression (Gu and 
Lupski, 2009; Itsara et al., 2009). Pathogenic CNVs that are too small to be detected 
with conventional cytogenic methods, but are above level of InDel-variants, are 
called microdeletions or microduplications vice versa. The simplest scenario is the 
deletion or disruption of one or more genes, which result in a functional loss. A 
microdeletion may lead to haploinsufficiency, unmasking pathogenic recessive 
mutations on the remaining homologues segment that have been silent in previous 
generations. Furthermore, regulatory elements may be disrupted or deleted, fusion 
genes can be generated at CNV breakpoints and lead to a gain-of-function mutation, 
or positional effects may influence gene expression of more distant genes unaffected 
by any CNV (Lupski and Stankiewicz, 2005; Feuk et al., 2006). Even a “two-hit” 
model of additional pathogenic CNVs contributing to a phenotype is conceivable 
(Girirajan et al., 2010, 2012). Pathogenic genomic duplications appear to be less 
common and seem to develop less severe phenotypes than microdeletions, although 
they might be under-diagnosed so far (Cook and Scherer, 2008; Slavotinek, 2008). 
Since only a limited number of rare CNVs have been successfully associated with 
disease, it is most likely that considerable amount of rare CNVs account for the 
‘common disease-rare variant’ hypothesis (Itsara et al., 2009). 
1.5 Genomic microdeletions in genetic generalized epilepsy 
The first pathogenic CNV locus that was associated with GGE was a recurrent 
microdeletion at 15q13.3, which was found in 12 of 1,223 and none of 3,699 
controls (Helbig et al., 2009). Despite being the first CNV associated with GGE, this 
microdeletion is still the most prevalent risk factor for common epilepsies. The 
reported 15q13.3 microdeletion has been reported before in association with 
mental retardation and seizures (Sharp et al., 2008), and schizophrenia 
(Schizophrenia Consortium, 2008; Stefansson et al., 2008). Following studies 
emphasized the pathogenicity of the reported microdeletion (Dibbens et al., 2009) 
and highlighted its phenotypic variability (Miller et al., 2009; Pagnamenta et al., 
2009). 
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Association with GGE was subsequently detected with microdeletions at 15q11.2 
and 16p13.1 (de Kovel et al., 2010), both microdeletions previously reported in 
neuropsychiatric disorders; microdeletions at 15q11.2 associated with 
schizophrenia (Stefansson et al., 2008; Kirov et al., 2009; Need et al., 2009), 
microdeletions at 16p13.11 associated with autism spectrum disorder (Sebat et al., 
2007; Ullmann et al., 2007), mental retardation (Ullmann et al., 2007; Hannes et al., 
2009), and with schizophrenia (Need et al., 2009). In addition, microdeletions at 
1q21.1 previously reported in schizophrenia and mental retardation (Brunetti-Pierri 
et al., 2008; Mefford et al., 2008; Schizophrenia Consortium, 2008; Stefansson et al., 
2008; Need et al., 2009), microdeletions at 16p11.2 identified in autism and mental 
retardation (Sebat et al., 2007; Kumar et al., 2008; Marshall et al., 2008; Weiss et al., 
2008), and microdeletions at 22q11.1 associated with schizophrenia, mental 
retardation and autism (Bassett et al., 2008; Schizophrenia Consortium, 2008; Kirov 
et al., 2009; Need et al., 2009), showed some suggestive evidence, but no association 
with GGE. Altogether, CNVs associated with GGE collectively explain a larger portion 
of the genetic variance epilepsy syndromes than any single gene (de Kovel et al., 
2010; Poduri and Lowenstein, 2011b). 
Recurrent microdeletions associated with genomic disorders share similar 
mechanisms and structures and are mostly mediated by NAHR (Mefford and Eichler, 
2009), although they show a high variability in phenotypes (Mefford et al., 2010). 
Therefore other risk factors, environmental and genetic modifiers are likely to 
contribute to the outcome of disease (Mefford and Eichler, 2009; Mefford and 
Mulley, 2010). 
In addition, smaller structural aberrations have been reported that only affect single 
genes or only single exons. Deletions in NRXN1 have been associated with a broad 
spectrum of neurodevelopmental and psychiatric disorders including schizophrenia, 
autism spectrum disorder, and intellectual disability (Kirov et al., 2009; Rujescu et 
al., 2009; Ching et al., 2010). In some cases, comorbidity of epilepsy was reported 
(Ching et al., 2010; Gregor et al., 2011) and compound NRXN1 mutations combining 
heterozygous exonic microdeletions and nonsense or splice-site mutations have 
been described in individuals with severe early onset epilepsy and mental 
retardation (Harrison et al., 2011; Duong et al., 2012). Neurexins are neuronal 
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adhesion molecules, required for synaptic contacts and efficient neurotransmission 
in the brain. They are located in the presynaptic terminal where they interact with 
postsynaptic neuroligins to form a transsynaptic complex (Südhof, 2008). 
Structural variations disrupting the gene encoding the neuronal splicing regulator 
RBFOX1 have been reported in three patients exhibiting epilepsy in comorbidity 
with autism, intellectual disability, or pontocerebellar hypoplasia (Bhalla et al., 
2004; Martin et al., 2007a; Gallant et al., 2011). Additionally, a linkage locus for 
photoparoxysmal response in GGE families has been mapped to the genomic region 
of RBFOX1 at 16p13.3 (Pinto et al., 2005). RBFOX1 is a splicing regulator gene, 
involved in the splicing of many neuronal transcripts, binding the sequence 
(U)GCAUG in introns flanking alternative exons (Jin et al., 2003; Auweter et al., 2006; 
Voineagu et al., 2011; Fogel et al., 2012). It is crucial for regulation of neuronal 
excitation and has a notably impact on susceptibility of epilepsy (Gehman et al., 
2011; Voineagu et al., 2011), as several target transcripts of RBFOX1 (for example, 
DCX, GABRG2, GAD2, GRIN1, KCNQ2, SCN8A, SLC12A5, SNAP25, SV2B, and SYN1) are 
correlated with epileptogenesis (Barnby et al., 2005; Corradini et al., 2009; Papale et 
al., 2009; Pandolfo, 2011; Fogel et al., 2012; Veeramah et al., 2012). Brain-specific 
homozygous and heterozygous Rbfox1 knockouts in mice do not alter brain 
morphology, but show differentially spliced RNA transcripts and display 
spontaneous seizures and a dramatic epileptogenic response to kainic acid resulting 
in status epilepticus (Gehman et al., 2011). Consequently, RNA interference–
mediated 50% knockdown of RBFOX1 transcripts in human neurons changes the 
alternative splicing pattern and expression of primarily neuronal genes involved in 
synapse formation and function (Voineagu et al., 2011; Fogel et al., 2012). 
1.6 Objectives 
This study was aimed at the identification of novel genomic loci associated with 
common GGE syndromes. To achieve this goal, two strategies for identifying genetic 
factors underlying complex disease were pursued:  
i) GWAS meta-analyses of two primary GWAS GGE data sets comprising a GGE case-
control cohort and a family-based study group. In addition to the global analysis, 
phenotypically distinct GGE subgroups, such as genetic absence epilepsies (GAE, 
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comprising CAE and JAE) and juvenile myoclonic epilepsies (JME), were to be 
analyzed separately to distinguish genetic factors, which may differentially 
predispose to particular GGE subtypes. 
ii) candidate variant/gene testing to investigate the impact of structural 
microdeletions on the etiology of common genetic epilepsies. Large recurrent 
microdeletions previously reported in neuropsychiatric disease were to be analyzed 
to detect association with GGE. Additionally, two potential candidate genes for GGE 
(NRXN1, RBFO1) were to be screened for exonic microdeletions to identify novel risk 
factors for epileptogenesis. 
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2 Methods and Materials 
2.1 Study Participants 
Epilepsy patients of European ancestry with common GGE syndromes (GAE with 
age-at-onset 3-20 years, JME with age-at-onset 6-20 years and EGTCS alone with 
age-at-onset 8-30 years) were recruited in a multi-center effort from the European 
EPICURE Project (http://www.epicureproject.eu). Phenotyping and diagnostic 
classification of GGE syndromes were carried out according to EPICURE guidelines 
and standardized phenotyping protocols (http://portal.ccg.uni-koeln.de/ccg/ 
research/epilepsy-genetics/sampling-procedure/) (ILAE, 1989; Nordli, 2005; Berg 
et al., 2010). All study participants gave informed consent according to the 
regulations at their local institutional review boards. Individuals with a history of 
major psychiatric disorders (autism spectrum disorder, schizophrenia and affective 
disorder) or severe intellectual disability were excluded. 
Two independent, unrelated sample cohorts were available for analysis. First, a 
case-control study cohort consisting of 1,569 unrelated GGE cases of European 
ancestry (600 males, 969 females; Austria, n = 197; Belgium, n = 53; Denmark, n = 
95; Germany, n = 933; and The Netherlands, n = 291) and 6,201 German controls 
(3,142 males, 3,059 females). The epilepsy patients comprised the following GGE 
syndromes: 693 GAE, 625 JME, and 251 patients with EGTCS alone. The control 
cohort of 6,201 unscreened German controls were collected from Southern (PopGen, 
n = 1,625) (Wichmann et al., 2005), Northern (KORA, n = 1,163) (Krawczak et al., 
2006), and North-Eastern (SHIP, n = 3,413) (Völzke et al., 2011) regions of Germany. 
In addition, 566 parent-offspring trios of European origin with children affected by 
GGE were available for family-based association analysis (216 male trio children, 
350 females). Trios were recruited from Australia (n = 98), Austria (n = 3), Bulgaria 
(n=4), Denmark (n = 20), Finland (n=1), France (n=16), Germany (n = 15), Italy (n = 
272), Spain (n=4), and Turkey (n = 133). The trio sample cohort contained following 
syndromes: 317 GAE, 157 JME, and 92 trios with EGTCS alone. 
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2.2 Array-based SNP genotyping 
Microarrays for SNP genotyping usually have a similar design. An acryl or glass 
surface is carrying a large number of unique oligomer probes that are specific to a 
defined position on the genome, for example a SNP or a copy number region. Large 
groups of unique probes are forming so called features on the array surface. Sample 
DNA is amplified, fragmented and hybridized to complementary probes on the array 
surface. DNA fragments are stained with fluorescent nucleotides and/or with 
fluorescent antibodies. A laser based imaging system is used to collect fluorescent 
signals. Genotypes can be distinguished by the position of the signal, corresponding 
to the position of a probe feature, by signal intensity and by color if a two colored 
assay is used. Imaging data can now be analyzed by the software provided by the 
array manufacturer and is transformed into genotype, copy number or other 
applicable data. 
2.2.1 DNA preparation and quality control 
All DNA samples provided by the participating centers were quantified using the 
NanoDrop 1000 photometer (NanoDrop products, Wilmington, DE, USA) and the 
presence of high-molecular weight genomic DNA was examined by gel 
electrophoresis on 1%-agarose gels. DNA samples exhibiting a high degree of 
degradation (no distinct fragment band > 10 kb) were excluded from the 
experimental investigations. 
2.2.2 SNP genotyping using the Affymetrix Genome-Wide SNP Array 6.0 
The Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, 
USA) offers oligonucleotide probe features for 1.8 million specific genetic markers. 
Of those, more than 906,600 account for SNPs and 946,000 for non-polymorphic 
probes to detect copy number variations (CNVs). A total of 500 ng high quality 
genomic DNA is split in two aliquots and digested in parallel with two restriction 
enzymes (Nsp and Sty). The fragments are ligated to adaptors that recognize the 
cohesive 4 bp restriction overhangs. A generic primer that recognizes the adaptor 
sequence is used to amplify DNA fragments by Polymerase Chain Reaction (PCR) 
(Kennedy et al., 2003). PCR conditions have been optimized to preferentially amplify 
fragments in the 200 to 1,100 bp size range. PCR amplification products for each 
2 | Methods & Materials 
16 
restriction enzyme digest are combined and purified using polystyrene beads. The 
amplified DNA is then fragmented, labeled, and hybridized to a SNP6.0 microarray 
(Matsuzaki et al., 2004). After ligation, the arrays are stained and imaged. 
Raw data analysis and genotyping is performed by the Affymetrix Genotyping 
Console software (Affymetrix, Santa Clara, CA, USA). Raw data analysis is required to 
assure sufficient quality of the processed arrays, by evaluation of probe set signal 
intensity. Signal intensity is crucial for correct genotype calling. On the Affymetrix 
SNP6.0 array, the contrast QC value (cQC) represents the distribution of signal 
intensities for subset of representative SNPs. The same accounts for Nsp and Sty 
specific values, cQC-Nsp and cQC-Sty. Samples with any cQC value ≤ 0.4 have been 
excluded due to expected low raw signal quality. Genotyping is performed after 
filtering for quality of raw signal intensities. 
SNP genotyping is performed using the Birdseed algorithm (Korn et al., 2008), 
integrated in the Affymetrix Genotyping Console. Birdseed uses a customized (EM) 
algorithm to fit two-dimensional Gaussians to SNP data, producing genotypes and 
confidence scores for every individual at every SNP. 
2.2.3 SNP genotyping using the Affymetrix Axiom® Genome-Wide SNP array 
The Affymetrix Axiom® Genome-Wide HU genotyping array (Affymetrix, Santa Clara, 
CA, USA) is a two color, ligation-based assay utilizing 30-mer oligonucleotide probes 
synthesized in situ on a microarray substrate, with automated, parallel processing of 
96 samples per plate (Hoffmann et al., 2011). The Axiom® Genome-Wide Reagent v1 
array used in this study is carrying specific probe features for 567,096 SNPs. An 
amount of 200 ng high quality DNA is amplified by Whole Genome Amplification and 
digested by restriction Enzyme into fragments of 25-125 bp in size. DNA fragments 
form a probe-target complex on the array surface and are hybridized with SNP-site 
specific probes and ligated for specificity. Arrays are washed, stained and imaged 
after ligation. 
Raw data analysis is performed by the Affymetrix Genotyping Console software, 
similar to the Affymetrix SNP6.0 array. For evaluation of signal intensities of the 
Axiom® Genome-Wide array, the corresponding value is called DishQC. 
Manufacturer’s threshold for sample exclusion is specified at ≤ 0.82, although the 
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given threshold is not definitive. For the Axiom® array, samples with a marginal 
DishQC values have been genotyped and excluded on account of the Call Rate (CR) 
per sample. 
Genotyping is performed after filtering for quality of raw signal intensities by the 
Affymetrix Genotyping Console software, using the Birdseed algorithm (Korn et al., 
2008). 
2.3 Genome-wide association studies 
2.3.1 Array and SNP and quality control 
SNP microarray data required extensive quality control (QC) to ensure high data 
quality and to avoid formation of artifacts during imputing. Only samples with 
sufficient signal intensity ratio were used for further QC filtering (see 2.2.2, 2.2.3). 
Samples with CR < 95%, and excessive heterozygosity rate of autosomal SNPs > 
29.5%, were excluded from analysis. Unsuccessful gender assignment led to 
exclusion of the sample as contamination or bad sample quality was expected. 
Remaining samples were genotyped again to improve cluster distribution of the high 
quality samples. 
Within the family-based data set, trio pedigree structure and relationship of all trio 
members was checked with PedigreeExplorer (Steffens 2007; Institute for Medical 
Biometry, Informatics and Epidemiology (IMBIE) of the "Medizinische 
Einrichtungen der Universität Bonn", Bonn, Germany; http://pedigreeexplorer. 
meb.uni-bonn.de/)  and by IBD-estimation in PLINK (Purcell et al., 2007; 
http://pngu.mgh.harvard.edu/purcell/plink/). Based on this information, pedigree 
structure and sample permutations were corrected if possible or pedigrees excluded 
if necessary. 
SNPs with high genotyping accuracy were selected for SNP imputation according to 
the following QC criteria, with respect to the sample cohort and array type. 
Affymetrix SNP6.0 QC criteria: i) minor allele frequency (MAF) < 5% in cases or 
controls, ii) CR < 98% for SNPs with MAF > 10% and CR < 99% for SNPs with MAF < 
10% in either cases or controls, ii) difference of missing data >1% between the cases 
and controls, iv) deviation from the Hardy–Weinberg equilibrium (HWE) with P < 
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1.0 × 10-4 in the controls. Affymetrix Axiom QC criteria: i) MAF < 5%, ii) CR < 95%, 
iii) HWE with P < 1.0 × 10-6, Mendelian error rate > 5% with remaining Mendelian 
errors set to missing. 
2.3.2 Principal component analysis 
A study cohort with samples from different populations may be prone to effects by 
reason of differing SNP allele frequencies in those populations, called population 
stratification. Population stratification may occur due to geographical and cultural 
barriers that lead to discrete mutation, selection and genetic drift in separated 
populations. Thereby the founding of subpopulations is likely. Subpopulations can 
often be distinguished as ethnic groups, but further stratification may be hidden 
beneath an obvious superstructure. Those groups may differ crucial in their allele 
frequencies for genetic variations. As association analysis statistics are based on the 
comparison of differing allele frequencies, distinct origins in samples and especially 
between cases and controls may lead to false-positive results (Thomas and Witte, 
2002). In this case, association would display the difference between populations 
and no association with disease. 
Existing genome-wide SNP genotypes can be used to detect and correct for 
population stratification. Established methods are principal component analysis 
(PCA) and multidimensional scaling (MDS). As both methods yield comparable 
results (Wang et al., 2009) and genetic and geographical distances are well 
correlated in European populations, we decided to perform a PCA analysis with the 
EIGENSTRAT v3.0 software (Patterson et al., 2006; Price et al., 2006). The principle 
used by both methods is the summarization of available data (i.e. genotype 
information of a sample cohort) in principal components (PCA) or dimensions 
(MDS). Those are sorted by their amount of variance and correlated. The first 
dimensions are carrying the mayor information about the sample, with later 
dimensions tending towards 0. To assure that true population effects are explored, a 
high quality data set (SNP quality filters: CR > 0.99, MAF > 0.15, HWE with P > 10-3) 
is created with exclusion of markers in tight Linkage Disequilibrium (LD; r2> 0.1), 
markers that are located in known regions of long range LD patterns (Suppl. 6-2) 
and common inversion polymorphisms. 
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2.3.3 SNP imputing 
Imputing is a useful multipoint method that can detect causal variants that have not 
been directly genotyped by, for example, SNP-based DNA microarrays (Marchini et 
al., 2007). This approach improves statistical power of association analysis by 
predicting unobserved SNP genotypes using existing catalogs of variation and 
known haplotypes, such as the HapMap project (Altshuler et al., 2010) and the 
1000genomes project (Abecasis et al., 2012), as a reference panel. Equally 
important, imputation is an indispensable step for later meta-analysis, if studies 
based on different genotyping methods or arrays are combined. Different 
genotyping arrays only have a fraction of their SNPs overlapping in general. The 
reduction of a joined data set is avoided by imputing to a much larger marker set 
with a considerably increased marker overlap. 
 
Figure 2-1 | Plot of principal components 1 and 2 from PCA. Exemplary data plotted of principal 
components with largest effect in PCA. Cases in red, controls in black. 
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Imputation in this study was accomplished using IMPUTE v2 
(http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) (Howie et al., 2009), a 
method that uses a Markov chain Monte Carlo (MCMC) framework to predict 
untyped SNPs by combining a reference panel of individuals genotyped at a dense 
set of SNPs with a study sample collected from a genetically similar population and 
genotyped at a subset of these sites. The approach is based on an approximate 
population genetics model that gives more weight to genotypes that are consistent 
with the local patterns of LD. This approach uses information from all markers in LD 
with an untyped SNP, decreasing with genetic distance from the SNP being imputed 
(Marchini et al., 2007). The SNPTEST v2 software was used to calculate frequentist 
and bayesian tests used for quality filtering of SNP markers (Marchini et al., 2007). 
SNP markers were filtered for minor allele frequency, proportion of missing 
genotypes, and info score. The info score is a measure of the observed statistical 
information for the estimate of allele frequency of a SNP. All individuals in the 
sample are used to test each SNP with a maximum value of 1 for perfect information. 
 
Figure 2-2 | Simplified procedure of imputing (modified from Marchini 
et al., 2007, https://mathgen.stats.ox.ac.uk/impute/impute_v1.html) 
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Quality control of imputed data 
Imputed SNP genotypes were quality filtered again to maintain a high quality data 
set. Quality filtering of imputed data done with IMPUTE dosage data using SNPTEST 
v2 (Marchini et al., 2007). SNPs were excluded from further analysis according the 
following QC criteria: i) SNPtest info quality value < 0.9, ii) MAF < 3% (for cases and 
controls separately in the case-control cohort), iii) missing data proportion > 1%, iv) 
HWE deviation with P < 10-6 (in the case-control cohort, with P < 10-6 in the cases 
and P <10-4 in the controls). 
Imputing of Affymetrix SNP 6.0 array case-control data 
After SNP genotyping, the quality filtered data set consisted of 1523 cases and 2454 
controls (579 males, 944 females; cases with 705 GAE, 579 with JME, and 239 with 
EGCTS alone) with 572,071 SNP markers. The data set was imputed using IMPUTE 
v2, based on the reference panel: 1000 Genomes Phase I (interim) release in NCBI 
build 37 (hg19) coordinate (update 05 Mar 2012) by Dr. Carolien deKovel at the 
Department of Medical Genetics, Section Complex Genetics, University Medical 
Center Utrecht, The Netherlands. Imputed data was transferred to Cologne for 
further QC and association analysis. The final data set consisted of 5, 564,553 SNPs 
after post-imputing QC. 
Imputing of Affymetrix Axiom® SNP array trio data 
The quality filtered data set consisted of 566 trios and 553,012 SNP markers after 
SNP genotyping. The data set was imputed using IMPUTE v2, based on the reference 
panel 1000 Genomes Phase I (interim) release in NCBI build 37 (hg19) coordinate 
(update 19 Apr 2012) by Dr. Markus Leber at the IMBIE of the "Medizinische 
Einrichtungen der Universität Bonn", Bonn, Germany. Imputed data was transferred 
to Cologne for further QC and analysis. The final data set consisted of 5,776,102 
SNPs after post-imputing QC. 
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Data conversion for TDT analysis 
Data output format of IMPUTE is so called dosage data, presenting frequencies of AA, 
AB and BB genotypes for every single SNP per sample. For some analysis data had to 
be converted into Linkage data format, that features genotype base calls for every 
SNP. Data conversion was done with a custom Perl script (by Dr. Markus Leber, 
IMBIE of the "Medizinische Einrichtungen der Universität Bonn", Bonn, Germany), 
using the best genotype method. Dosage data alleles are converted into Linkage 
format, if the probability of the most likely genotype is at least 40% higher than that 
of the second likely genotype. Otherwise, genotype is set to missing. 
2.3.4 Case-control-based genome-wide association analysis 
The case-control data set in our study is equivalent to the Stage-1 data cohort of 
previously published GWAS (EPICURE Consortium et al., 2012a). Stage-1 data of this 
publication was selected for a meta-analysis with the TDT trio data surveyed by our 
study. An update in the imputing reference set required rerun of imputation 
procedures, and recalculation of statistical analysis for actuality and full 
compatibility with the trio data. 
While a high genomic inflation factor (GGE: λ = 1.11, GAE: λ = 1.05 and JME: λ = 
1.06) was reported from prior GWAS for association results of logistic regression 
analysis of our data (EPICURE Consortium et al., 2012a), genome-wide association 
was calculated using FaST-LMM (http://fastlmm.codeplex.com/) (Lippert et al., 
2011), a method using a factored spectrally transformed linear mixed-model that 
explicitly captures all sources of structure based on estimates of the genetic 
relatedness of individuals. Logistic regression for an additive model was performed 
by SNPTEST v2 to estimate Odds Ratios (OR) and confidence interval, using the first 
five principle components from PCA analysis and gender status as covariates. The 
signal intensity cluster plots of the most significantly associated SNPs (P < 1.0 × 10-5) 
were manually examined within the Affymetrix Genotyping Console. In total, 100 
SNPs exhibiting artificial cluster plots were excluded. 
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2.3.5 Family-based genome-wide association analysis 
SNP genotype dosage data were converted to best-genotype estimates due to the 
following conditional likelihoods of genotypes into linkage format with Perl. Data 
was quality filtered again, with CR ≥ 98% and a Mendelian error rate < 4% with 
remaining Mendelian errors set to missing. The final data set consisted of 566 
complete parent-offspring trios and 5,089,023 SNPs (216 male trio children, 350 
females; 317 GAE, 157 JME, and 92 trios with EGTCS alone); one trio was excluded 
due to increased rate of Mendelian errors. 
Genome-wide association was calculated by using the Transmission-Disequilibrium 
Test (TDT) in PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 
2007). This method is using data from families with at least one affected child to 
evaluate the transmission of a marker allele from a parent to an affected offspring 
(Spielman et al., 1993). The TDT considers parents who are heterozygous for an 
allele associated with disease and evaluates the frequency with which that allele or 
its alternate is transmitted to affected offspring. Test statistic is calculated by a 
variant of the χ2-Test, the McNemar’s test (McNemar, 1947). 
In contrast to classic χ2-test based approaches to test for association, the TDT 
remains valid and preserves the Type-I error rate, regardless of population history 
(Ewens and Spielman, 1995). However, population stratification will lead to a 
decrease in the number of heterozygous parents and will change the relative 
proportion of informative markers (Sebro and Rogus, 2010). This leads to a loss of 
statistical power by increasing the required sample sizes to achieve level of 
significance. TDT analysis was done in PLINK (http://pngu.mgh.harvard.edu/ 
purcell/plink/) (Purcell et al., 2007). The signal intensity cluster plots of the most 
significantly associated SNPs (P < 1 × 10-5) were manually examined within the 
Affymetrix Genotyping Console. In total, 24 SNPs exhibiting artificial cluster plots 
were excluded. 
2.3.6 Meta-analysis of case-control and family-based association studies 
A well-established tool to perform fast and reliable meta-analysis is METAL 
(http://www.sph.umich.edu/csg/abecasis/metal/index.html) (Willer et al., 2010). A 
key factor for meta-analysis is assigning appropriate weights to statistic results for 
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association for each combined study to indicate the effect size of the individual P-
values. The basic principle of meta-analysis is to combine the evidence for 
association from individual studies, using appropriate weights. METAL implements 
two different approaches for weighted analysis. For the first approach, the p-value 
and the direction of effect (in our study log(OR)) are converted into a Z-Score, with a 
negative Z-Score for large p-values and positive Z-Scores for small p-values. Z-scores 
for each allele are combined across samples in a weighted sum proportional to the 
square-root of the sample size for each study. The second approach weights the 
effect size estimates by their estimated standard errors. This second approach 
requires effect size estimates and their standard errors to be in consistent units 
across studies. Asymptotically, the two approaches are equivalent when the trait 
distribution is identical across samples (such that standard errors are a predictable 
function of sample size). Odds Ratios from logistic regression from case-control 
analysis and OR from trio TDT analysis were pooled using GWAMA 
(http://www.well.ox.ac.uk/gwama/index.shtml) (Mägi and Morris, 2010). 
Sample sizes and number of overlapping SNPs for genome-wide association meta-
analysis were as following: GGE 1523 cases, 2454 controls, 566 GGE trios, 4,224,196 
overlapping SNPs; GGE subtype analyses: GAE: 705 cases and 2454 controls, 317 
trios, 4,224,597 overlapping SNPs; JME: 579 cases, 2454 controls, 157 trios, 
4,220,447 overlapping SNPs. 
2.3.7 Relative risk and odds ratio 
The relative risk is an effect size for comparison of two groups in a given cohort that 
are exposed to a certain trait. The number of individuals developing an effect is 
measured over time (Viera, 2008). 
 
  
Table 2-1 | Calculating risk ratio and odds ratio in a cohort study 
 Develop outcome Do not develop outcome 
Exposed a b 
Not exposed c d 
Modified from Viera et al., 2008 
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The relative risk or risk ratio (RR) can be calculated as follows: 
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The same table can be used to calculate an odds ratio (OR). The OR represents the 
ratio between the probability (or odds) of the two groups to develop a certain trait: 
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RR and OR estimate the rate of risk or probability to develop a specific outcome. For 
RR = 3, the risk to develop the outcome is 3 times higher. For an OR = 3, the same 
accounts for the odds to develop the outcome. To estimate the statistical significance 
and accuracy of RR and OR calculation, it is recommended to calculate a confidence 
interval (CI, usually 95%). The CI is represented in a spectrum of values. In 95 out of 
100 observations, the OR would be between the upper and the lower CI values. ORs 
and CIs have been calculated using the R software environment (http://www.r-
project.org/). 
2.3.8 Genomic control 
The genomic control (GC) is an analytic method used to control the false positive 
rate in population-based association studies (Devlin and Roeder, 1999; Devlin et al., 
2004). To reduce the effect of stratification by experimental design and analysis, 
cases and controls should be matched for ethnicity and environmental covariates. 
GC then adjusts for the residual effects of stratification. A careful study design and 
implementation pay off in statistical power, though even small stratification can 
inflate association test statistics. The GC further eludes the need for Bonferroni 
correction for multiple testing, leading to better performance in many settings while 
still decreasing the risk for false positives. To apply GC to an association study, an 
inflation factor λ is calculated for the χ2 distribution under the hypothesis of no 
population stratification: 
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0.456  
The association statistics of single-marker P-values are therefore corrected by: 
χ

  =λ ∗ χ
 
2.3.9 Power calculations 
Power calculations for GWAS were performed using CaTS power calculator 
(http://www.sph.umich.edu/csg/abecasis/CaTS/) (Sebro and Rogus, 2010). Case-
control GWAS for GGE has a power of 80% to detect a variant associated with 
disease on OR ≥ 1.40, with significance threshold of P ≤ 5 × 10-8, assuming a 
prevalence of 0.3%, an additive genetic model, and frequency of disease-associated 
allele of ≥ 20% in unaffected controls. For the GAE subgroup, 80% power is achieved 
for OR ≥ 1.57 under identical parameters, for JME subgroup at OR ≥ 1.64. Within trio 
analysis, GGE trios have 80% power to detect a variant with OR ≥ 1.87, for GAE trios 
with OR ≥ 2.35, and for JME trios with OR ≥ 3.60 (estimation on a pseudo-case-
control partition of transmitted to untransmitted alleles). Genome-wide meta-
analysis obtained 80% power for GGE with OR ≥ 1.34, for GAE with OR ≥ 1.47, and 
for JME with OR ≥ 1.56. Sizes of sample cohorts are as follows: Case-control analysis 
of GGE: 1,523 cases vs. 2,454 controls, GAE: 705 cases vs. 2,454 controls, JME: 579 
cases vs. 2454 controls; TDT analysis of GGE: 556 cases, GAE: 317, JME: 157; meta-
analysis of GGE: 2,089 cases vs. 3,020 controls, GAE: 1,022 cases vs. 2,771 controls, 
JME: 736 cases vs. 2,611 controls. 
Detailed power calculations of case-control, TDT and meta-analysis were performed 
with the PGA2 software (http://dceg.cancer.gov/tools/analysis/pga) (Menashe et 
al., 2008). Minimal detectable OR at 80% power for GGE, GAE and JME are shown in 
Figure 2-3. Power calculations were performed as above, assuming a disease 
prevalence of 0.3%, the additive risk model and r2 = 0.9 between a causal variant 
and a genotyped. 
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2.3.10 GWAS significance threshold and presentation of results 
Threshold for genome-wide significance was set to P ≤ 5 × 10-8, for suggestive 
association to P ≤ 1 × 10-5 (McCarthy et al., 2008). Results were plotted as Manhattan 
and QQ-plots with a custom R script (qqman.r by Stephen Turner, 2011, University 
of Virginia, http://GettingGeneticsDone.blogspot.com/). Regional details of 
significant results to show local LD structure were created using LocusZoom 
(http://genome.sph.umich.edu/wiki/LocusZoom) (Pruim et al., 2010). 
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Figure 2-3 | Detectable Odds Ratios for genome-wide association of TDT, case-control and meta-analysis in 
GGE, GAE and JME 
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2.4 Copy number analysis 
2.4.1 Copy number analysis using Affymetrix SNP6.0 arrays 
Beside more than 900,000 SNP probes, the Affymetrix SNP6.0 array features 
946,000 non-polymorphic Copy Number Polymorphism (CNP) markers to detect 
CNVs. CNV calling was performed by the Affymetrix Genotyping Software using the 
Birdseye algorithm (Korn et al., 2008). Birdseye is a Hidden Markov Model (HMM) to 
find regions of variable copy number in a sample. The hidden state is the true copy 
number of the individual’s genome; the observed states are the normalized intensity 
measurements of each probe on the array. Intensity measurements therefore allow 
for differentiation between normal CNV state, CNV losses or CNV gains. Breakpoint 
estimation of CNV segments is not exact and depends on probe resolution of the 
observed segment and CNV calling performance is heavily dependent on the general 
number of markers called. Hence large CNVs with a high number of array probe sets 
and a high resolution yield higher detection confidence. Only samples arrays 
fulfilling the GWAS array QCs were included in CNV analyses. 
After CNV calling and segmentation, CNV segments were quality filtered. Only 
segments with ≥ 20 SNP and/or CNP markers and ≥ 40 kb in size were kept for 
analysis. For CNVs with less markers and smaller in size, false-positive error rate is 
expected to exceed a reasonable level. CNVs with a minimum of 20 markers and 40 
kb are expected to be relatively valid, even if the arrays were processed at different 
laboratories (Pinto et al., 2011). Centromere-spanning CNVs were eliminated from 
the data, as they represent typical technical artifacts. 
2.4.2 Loss-of-Heterozygosity screening to predict recurrent microdeletions 
In case of a genetic microdeletion, all heterozygous SNP genotypes are lost due to 
the loss of one homologous chromosomal strand in the affected region, leading as 
well to LOH. The co-occurrence of deletions and LOH is used as an additional marker 
together with signal intensity in various algorithms for CNV calling (Colella et al., 
2007; Wang et al., 2007). 
For the Affymetrix Axiom Genome-Wide array, CNV calling is not supported by the 
standard software. Technical limitations of the array, in particular the low 
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redundancy of probe features for the benefit of small array size, are complicating 
normalization procedures and CNV calling. Although a successful approach is 
reported for the Axiom Bovine array in cattle (Rincon et al., 2011), our own efforts 
were unsuccessful. To date, no method is available for analysis of human CNVs with 
Axiom Genome-wide arrays. Using the genotype information acquired with Axiom 
arrays, a screening for LOH is practical by implication. Individuals carrying a LOH in 
a defined region where genomic deletions have been reported previously are 
considered to be possible deletion carriers as well. Chances of success have been 
estimated by frequency of reported deletions in affected and unaffected individuals. 
In addition, Mendelian errors are additional evidence for occurrence of deletions in 
trios. LOH analysis was performed using PLINK (http://pngu.mgh.harvard.edu/ 
purcell/plink/) (Purcell et al., 2007). 
To increase consistency of the LOH analysis, we genotyped our samples with a 
decreased Confidence score. The Confidence score with a value between 0 and 1 
represents the ratio of the distance from the closest cluster to the second closest 
cluster during genotyping. Lower values are more confident, larger values of the 
confidence threshold indicate less certain calls. Calls with Confidence scores above 
the threshold are assigned a no-call. To obtain higher genotype reliability, we 
changed the Confidence score for the LOH analysis data set from 0.15 to 0.005. 
PLINK LOH analysis results in a summary table for each LOH region per sample, 
including position, size, marker density and rate of homozygous and heterozygous 
markers that were used for candidate selection. In addition, we calculated a score by 
taking into account the ratio of heterozygous to non-heterozygous (including 
missing genotypes). We assume, that for a LOH with a given set of markers the 
homozygosity rate is PHOM = 1, together with a heterozygosity rate PHET = 0 and vice 
versa. With an increasing number of missing (non-informative) markers (PMISS), we 
expect the reliability of genotype calls to decrease as well as the impact of observed 
heterozygous makers. To take this into account, we calculated a score value called 
SHET to represent the ratio of heterozygous markers PHET multiplied with the ratio of 
heterozygous PHET to non-heterozygous markers (PHET + PMISS): 
 =  ∗   +  !""# 
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where (PHET + PMISS) > 0.The more markers are non-informative or missing, the 
smaller the ratio PHET versus (PHET + PMISS), the lesser the effect of PHET in the 
observed region of LOH. By multiplying PHET with the ratio PHET versus (PHET + PMISS), 
the effect size of PHET is shown under the impact of PMISS. As follows: 
 =  ∗   +  !""# =


1 − &  
where (PHET + PMISS) > 0, PHOM< 1. As for PHET, a SHET = 1 represents a heterozygous 
and SHET = 0 a homozygous site, but with regard to the occurrence of heterozygous 
markers in relation to the number of missing genotypes as an indicator for a low 
regional genotype quality.  
Screening for LOHs to identify possible deletion carriers required verification of 
microdeletions by additional methods. 
2.4.3 Quantitative real-time PCR 
Reliable quantitative analysis of a specific gene or region is a critical aspect for Copy 
Number analysis. Although DNA microarrays are very efficient, they are often too 
expensive for an explicit screening of a small region of interest and their results 
require confirmation. Quantitative Polymerase Chain Reaction (qPCR) is a powerful 
tool for this task. We used TaqMan® Copy-Number assays (Applied Biosystems, 
Lifetech, USA) for a specific real-time qPCR setup with an internal reference for each 
single reaction. 
The qPCR reaction is performed with the Applied Biosystems7900HT Sequence 
Detection System, according to standard protocol (Determining Gene copy number 
using TaqMan® real-time PCR assay on the7900HT, ABI 2006). TaqMan® CN assays 
consist of an oligonucleotide primer pair specific to the region of interest and an 
unique probe that will bind between primers during qPCR reaction. The probe 
works of the Fluorescence resonance energy transfer (FRET) principle and features 
fluorescent donor and molecules. During qPCR, the probe binds to the DNA target 
sequence and is destroyed during elongation phase. This separates the donor from 
the acceptor changing the emitted fluorescence signal, which is measured at the end 
of the elongation phases. For Copy Number estimation, a reference reaction with the 
highly conserved single copy RNase P gene is performed within the same reaction 
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well. Copy Number of the samples is calculated by comparison of signal intensity 
change over time for the target assay against the reference RNase P assay. Each 
sample is analyzed as a triplet (or quadruplet if required by assay performance) in 
order to obtain a sufficient statistical basis for data analysis The SDS software and 
CopyCaller software (both Applied Biosystems, Lifetech, USA) are used for analysis 
and presentation of results. 
2.4.4 Array comparative genomic hybridization 
Array comparative genome hybridization (aCGH) is a well-proven method for CNV 
detection and validation (Itsara et al., 2009). In contrast to SNP based microarray CNV 
analysis, aCGH supplies better results for breakpoint estimation and a higher confidence 
of results. All aCGH assays are based on the comparison of two distinct labeled samples, 
one target and one reference sample. Sample are hybridized to one array carrying long 
oligonucleotide (Sebat et al., 2004) or bacterial artificial chromosome (BAC) clone 
(Iafrate et al., 2004) target features. Signal intensity ratio of both samples is used as a 
proxy for CNV detection. A well described reference sample is essential, as unreported 
CNVs in the reference may lead to identification of false-positive variants in the target 
sample. Array CGH analysis applied in this study has been performed in the laboratory 
of Heather Mefford in the Department of Pediatrics, Division of Genetic Medicine at the 
University of Washington in Seattle. 
2.4.5 Association tests based on contingency tables 
A contingency table displays the frequency distribution of continuously variables to 
be tested. Those variables are tested to fit a null hypothesis, an expectation that is 
fulfilled if the observed values are equal to the expected ones. If applicable, 
Pearson’s χ2-test is used. As for frequency distributions of ≤ 5 Pearson’s χ2-test 
yields no exact results, Fisher’s exact test is used. Calculation of p-values was 
performed with standard functions for χ2-test and Fishers exact test within the R 
software environment (http://www.r-project.org/). 
Where applicable, threshold for significance has to be adjusted for multiple testing. 
This is done using the method from Bonferroni (Bland and Altman, 1995), were the 
threshold for significance is 0.05 / number of tests. 
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2.4.6 Analysis of recurrent microdeletions 
Six recurrent microdeletions were selected for evaluation of contributing to risk for 
IGE. An excess of these six large candidate microdeletions has been previously 
reported in a wide spectrum of neuropsychiatric disorders including autism, 
intellectual disability and schizophrenia (Ullmann et al., 2007; Cook and Scherer, 
2008). The selection of microdeletions at 1q21.1 (Brunetti-Pierri et al., 2008; 
Mefford et al., 2008; Schizophrenia Consortium, 2008; Stefansson et al., 2008; Need 
et al., 2009), 15q11.2 (Stefansson et al., 2008; Kirov et al., 2009), 16p11.2 (Sebat et 
al., 2007; Kumar et al., 2008; Marshall et al., 2008; Weiss et al., 2008), 16p13.11 
(Ullmann et al., 2007; Hannes et al., 2009; Need et al., 2009) and 22q11.2 (Bassett et 
al., 2008; Schizophrenia Consortium, 2008; Need et al., 2009) was based on previous 
copy number variation and a CNV meta-analyses (Itsara et al., 2009), and required 
following inclusion criteria: Recurrent microdeletion mediated by NAHR (equal in 
size and with defined breakpoints); previous association of the microdeletion with 
neuropsychiatric disorders (P < 0.05), and size of the deletion larger than >400 kb to 
ensure a reliable detection by the Affymetrix SNP 6.0 array. Microdeletions were 
considered to match the published deletions if they overlapped at least 85% of the 
genomic region of the candidate microdeletion (Table 2-1). 
Initially, Affymetrix SNP6.0 array data of 1523 GGE samples and 2454 controls were 
selected for CNV analysis. Candidate microdeletion studies have been published 
previously for smaller subsamples of this ongoing research project (Helbig et al., 
2009; de Kovel et al., 2010). The sample cohort used in our study is identical with 
the case-control cohort used for GWAS and meta-analysis, and thus did undergo 
same QC parameters that were applied prior to imputing. In addition, we added 
Affymetrix SNP6.0 array data of 3,413 additional unrelated German controls from 
the SHIP cohort, which underwent the same QC filtering procedures. SHIP samples 
were combined with the data set of the GWAS case-control cohorts and were 
examined for stratification by PCA. 
Copy Number calling was performed with the Affymetrix Genotyping Console. To 
ensure quality of CNV calls, only CNV segments with more than 20 markers and at 
least 40 kb in size were taken into account. Samples with a high number of CNVs 
(number of CNVs per sample > average number of CNVs of all samples ± 3 SD) and 
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an excessive CNV load (total size of CNVs per sample > average total size of CNVs of 
all samples ± 3 SD) were excluded from the analysis. After filtering, 1497 IGE 
samples and 5374 controls (KORA n = 1348, PopGen n = 1079, SHIP n = 2947) 
remained. 
Candidate regions were then explored for CNV segments. Changes of the 
heterozygosity state and log2 ratios along with candidate deletions were visually 
inspected to exclude technical artifacts. Identified CNV segments were validated 
with quantitative real-time PCR. Cross validation and exact breakpoint estimation 
were performed with array Comparative Genomic Hybridization. Association 
analyses between genotype and phenotype were carried out by two-sided χ2-tests 
or Fisher's exact tests where appropriate. If available, additional family members of 
microdeletion carriers were screened with either qPCR and/or aCGH for segregation 
analysis. Pedigree figures were generated with HaploPainter (http://haplopainter. 
sourceforge.net/) (Thiele and Nürnberg, 2005). 
 
2.4.7 Family-based analysis of large recurrent microdeletions 
A family-based study based on 566 parent-offspring trios with European origin was 
performed to further evaluate the frequency of the reported six recurrent 
microdeletions and to explore their pattern of inheritance. A standardized method 
for CNV calling was not available, due to the specifications of the Axiom array with 
Table 2-2 | Candidate regions for recurrent microdeletions 
Chr. segment Chr. position 
(Mb) 
MicroDel size 
(Mb) 
Candidate gene Neuropsychiatric 
disorder 
1q21.1 146.5-147.9 1.35 GJA5, GJA8, 
HYDIN2 
ID, SZ 
15q11.2 22.75-23.2 0.45 CYFIP1 SZ 
15q13.3 30.9-32.5 1.50 CHRNA7 ID/EPI, SZ, ASD 
16p11.2 29.6-30.2 0.70 KCTD13, PRRT2 
TAOK2 
ASD, ID 
16p13.11 14.8-16.4 1.60 NDE1 ID, SZ, ASD 
22q11.2 19.2-22.2 3.00 COMT, SNAP29 SZ, ID, ASD 
ID: Intellectual Disability; SZ: Schizophrenia; EPI: Epilepsy; ASD: Autism Spectrum Disorder; 
Chromosomal position in NCBI built 37.3, hg 19. 
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which the trios were called. Thus, screenings for LOH within candidate regions (at 
1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p13.11 and 22q11.2) was performed by 
PLINK (Purcell et al., 2007), to identify potential deletion carriers. For all 566 trios, 
genotype calling was repeated with an increased threshold for calling confidence 
(Affymetrix genotyping confidence value ≤ 0.005) to decrease the number of false 
genotype calls in the hemizygous regions. In total 326,123 SNPs fulfilling high QC 
filters were used for LOH screening. 
LOH screening was performed within breakpoints of previously reported 
microdeletions, given by reported breakpoints and smallest possible overlap of 
known deletion carriers. In addition, an extended region of including each 1 Mb 
distal and proximal from the microdeletion was screened to identify deletions with 
deviating starting and/or ending positions. Well characterized deletion carriers 
from previous screenings were used to assess inclusion criteria for each region 
individually by rate of heterozygous genotypes and number of Mendelian errors per 
region (Table 2-3). Moreover, we applied a score called SHET as auxiliary criteria to 
take the ratio of heterozygous to missing genotypes into account (see 2.4.2). Only 
samples with at least 85% overlap to a region with recurrent microdeletions were 
selected as microdeletion candidates. For validation of deletions, all trio members 
were genotyped with qPCR. 
2.4.8 Penetrance estimations for copy number variants 
For a detailed risk assessment, we assessed the penetrance of each candidate 
microdeletion. The penetrance of the microdeletions associated with GGE was 
estimated by a Bayesian approach previously reported for schizophrenia (Vassos et 
al., 2010). The probability P for developing a disease D for individuals carrying a 
CNV genotype G versus controls is calculated by the formula: 
((|*) = (*|()(()(*|()(() + (*|Ḋ)P(Ḋ) 
Confidence intervals for penetrance estimations were calculated with the Clopper–
Pearson exact tail area method (Rosenfeld et al., 2012) using the R software 
environment. 
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2.4.9 Candidate gene approach to detect exon-ablating microdeletions 
Exon-ablating microdeletions in NRXN1 
To analyze the impact of exon-disrupting/removing microdeletions in NRXN1 
(2p16.3, 50,145,643 – 51,259,674, hg19), this candidate gene study includes 1,569 
unrelated GGE cases of European ancestry and 6,201 German controls. All samples 
were genotyped with the Affymetrix SNP6.0 array, CNV analysis was performed by 
the algorithm implemented in the Affymetrix Genotyping Console. Segments with 
>20 markers and >40 kb in size were considered as highly confident CNV calls. 
Changes of the log2 signal intensity ratios of the NRXN1 microdeletions were 
manually inspected to exclude technical artifacts. All exonic NRXN1 microdeletions 
identified in the patient cohort were verified by TaqMan qPCR (NRXN1 exon 4 
Hs04683030_cn; Applied Biosystems, Foster City, CA, U.S.A.) and/or aCGH. For 
segregation analysis, all available family members were typed by qPCR and/or by 
aCGH. Pedigree figures were generated with HaploPainter (http://haplopainter. 
sourceforge.net/) (Thiele and Nürnberg, 2005). 
  
Table 2-3 | Position and inclusion criteria for LOH screening of deletion candidates 
Region  Start Mb End Mb #SNPs PHET SHET Mendel 
errors 
1q21.1 core 146.5 147.9 185 ≤ 0.02 ≤ 0.01 ≥ 5 
 extended 145.5 148.9 200 < 0.01 < 0.01 ≥ 10 
15q11.1 core 22.8 23.1 43 ≤ 0.025 ≤ 0.03 ≥ 4 
 extended 21.8 24.1 150 ≤ 0.02 ≤ 0.02 ≥ 1 
15q13.3 core 31.2 32.5 148 ≤ 0.035 ≤ 0.01 ≥ 17 
 extended 30.2 33.5 488 < 0.01 < 0.01 ≥ 1 
16p11.2 core 29.6 30.3 8 ≤ 0.01 ≤ 0.01 ≥ 1 
 extended 28.6 31.3 55 ≤ 0.01 ≤ 0.01 ≥ 2 
16p13.1 core 14.8 16.4 145 ≤ 0.025 ≤ 0.02 ≥ 10 
 extended 13.8 17.4 426 ≤ 0.01 ≤ 0.01 ≥ 10 
22q11.2 core 19.5 21.3 88 ≤ 0.01 ≤ 0.01 ≥ 17 
PHET: Proportion of heterozygous genotypes per LOH segment, SHET: Heterozygosity score per LOH 
segment, #SNPs: Number of SNPs in the genomic region of interest. Physical position NCBI built 37.3, 
hg19. 
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Exon-ablating microdeletions in RBFOX1 
Finally, the study consisted of 1,408 unrelated GGE patients of European ancestry 
(869 females, 539 males; CAE n = 413, JAE n = 207, GAE n = 7, JME n = 557, EGTCS n 
= 224) and 2,256 German population controls (1,077 females, 1,179 males). The 
control cohort of 2,256 German controls were collected from Southern (KORA, n = 
1,185) (Wichmann et al., 2005) and Northern (PopGEN, n = 1,071) (Krawczak et al., 
2006) regions of Germany. 
All samples were genotyped with the Affymetrix SNP6.0 array, CNV analysis was 
performed by the algorithm implemented in the Affymetrix Genotyping. Segments 
with >20 markers and >40 kb in size were considered as highly confident CNV calls. 
We included only arrays which revealed genome-wide less than 50 microdeletions 
(> 20 markers, > 40 kb) (Elia et al., 2012).  
All samples were screened for RBFOX1 (16p13.3, 6,069,132 – 7,763,340, hg19) 
deletions affecting the genomic sequence of the gene. All potential RBFOX1 
microdeletions were manually inspected for the regional SNP heterozygosity state 
and log2 ratios of the signal intensities to exclude technical artifacts. Subsequently, 
the copy number state of all RBFOX1 microdeletions identified was examined by 
qPCR, using seven TaqMan CNV assays covering the 5’-terminal RBFOX1 exons 1-4 
(Hs04461212_cn, Hs03952094_cn, Hs03929445_cn, Hs03930287_cn, Hs03948431_cn, 
Hs04457208_cn, Hs05452109_cn; Applied Biosystems, Foster City, CA, U.S.A.). For 
segregation analysis, all available family members were typed by qPCR and/or by 
aCGH. Pedigree figures were generated with HaploPainter (http://haplopainter. 
sourceforge.net/) (Thiele and Nürnberg, 2005). 
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3 Results 
3.1 Genome-wide association and meta-analysis 
3.1.1 Genome-wide association and meta-analysis of GGE patients 
Genome-wide association studies were performed to identify common variants 
associated with GGE. Therefore, we analyzed two GWAS datasets: i) a case-control 
study with 1,523 European GGE cases and 2,454 German controls and ii) a family-
based study with 566 parent offspring trios affected with GGE. Subsequently, GWAS 
meta-analysis was carried out by combining the SNP P-values of both GWAS 
datasets. The case-control data set in our study is equivalent to the Stage-1 data 
cohort of a previously published GWAS (EPICURE Consortium et al., 2012a). 
Case-control GWAS of GGE 
The GWAS of 1,523 GGE cases and 2,454 controls included 5,563,867 quality filtered 
SNPs. Using a LMM association statistic, no SNP reached the threshold for genome-
wide significance (LMM P < 5.0 × 10-8). , but 44 SNPs reached the threshold for 
suggestive association (LMM P < 1.0 × 10-5) (Table 3-1, Figure 3-1). The most 
significant association occurred on chromosome 2p16.1 in an intergenic genomic 
region with no gene as close as 100 kb (rs35577149, chr2:57,931,347, LMM P = 2.60 
× 10-6, OR[C] = 0.78, 95% CI 0.71 – 0.86). Genomic inflation factor was 0.998 and 
therefore no genomic correction applied (see QQ-plot in Suppl. 6.3.1). 
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Table 3-1 | Genome-wide association results of LMM P < 1.0 × 10
-5
 in GGE 
SNP CHR POS Allele 
A1/A2 
Source Info LMM P OR 
(95% CI) 
Gene 
rs35577149* 2 57,931,347 C/T Imp 1.00 2.60E-07 0.78 (0.71-0.86)  
rs388556* 2 13,392,540 G/C Geno 1.00 1.12E-06 0.76 (0.68-0.84)  
rs3106317 8 24,123,239 G/C Geno 1.00 2.35E-06 0.76 (0.67-0.86) ADAM28(28.3k) 
rs12495872* 3 13,121,129 A/G Imp 0.99 2.43E-06 0.66 (0.56-0.78) IQSEC1(6.5k) 
rs11890028 2 166,943,277 G/T Imp 0.96 2.53E-06 0.77 (0.70-0.85) SCN1A(13.1k) 
rs2268330 14 23,795,976 G/C Geno 1.00 2.89E-06 1.30 (1.17-1.44) PABPN1(0.6k) 
rs75414440 8 89,603,781 G/A Imp 0.99 5.23E-06 1.43 (1.21-1.69)  
rs35803605* 2 38,760,917 A/G Imp 0.97 5.36E-06 0.76 (0.67-0.85) HNRPLL(29.4k) 
rs3818509* 9 130,670,532 T/C Imp 0.97 5.58E-06 0.70 (0.60-0.81) ST6GALNAC4 
rs2254349* 13 111,987,226 C/G Imp 0.97 5.84E-06 0.81 (0.74-0.89) C13orf16 
rs1170543 1 34,744,384 C/G Imp 1.00 9.50E-06 1.27 (1.14-1.42) C1orf94(59.7k) 
rs289034 5 114,122,165 C/T Geno 1.00 9.60E-06 0.80 (0.73-0.88)  
CHR: Chromosome, POS: Physical position NCBI built 37.3 hg19, Allele A1: Minor allele, Allele A2: Major 
allele, Imp: SNP imputed, Geno: SNP genotyped, Info: SNPtest info value, Gene: Gene nearby the 
associated SNP, distance in brackets. The top-ranked SNP was represented in regions with several single 
marker association signals exceeding LMM P < 1.0 × 10
-5
 (*). 
 
Figure 3-1 | Manhattan plot of genome-wide association results in 1,523 GGE cases versus 2,454 controls. 
The x–axis shows the genomic position of SNP markers on chromosomes 1 to 22 (NCBI built 37.3, hg19), 
the y-axis shows the negative log10 of the single marker P-value of the linear mixed model (LMM) 
association statistic. The blue line represents the threshold for a suggestive association with P < 1.0 ×10
-5
, 
the red line for significant association with P < 5.0 × 10
-8
. 
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Family-based GWAS of GGE 
The transmission disequilibrium association test was performed for 566 GEE trios. 
The GWAS included 5,098,823 quality-filtered SNPs. No genome-wide significance 
was observed, but 64 SNPs showed suggestive association (Table 3-2, Figure 3-2). 
The lowest TDT P-value was detected on chromosome 8q12.2 (rs13266191, 
chr8:59,024,803, TDT P = 4.14 × 10-7, OR[A] = 0.50, 95% CI 0.38 – 0.66) within the 
genomic sequence of FAM110B. All P-values were corrected for genomic inflation (λ 
= 1.015, see QQ-plot in Suppl. 6.3.1). 
 
Table 3-2 | Genome-wide association results of TDT P < 10
-5
 in GGE 
SNP CHR POS Allele 
A1/A2 
Source Info TDT P OR 
(95% CI) 
Gene 
rs13266191* 8 59,024,803 A/G Imp 0.97 4.14E-07 0.50 (0.38-0.66) FAM110B 
rs8071170* 17 53,420,489 G/A Imp 0.99 2.89E-06 1.51 (1.27-1.80) HLF(18.1k) 
rs8002187* 13 61,602,325 C/T Imp 0.99 3.71E-06 1.50 (1.26-1.78)  
rs2861858* 18 36,702,626 G/A Imp 0.97 5.16E-06 0.67 (0.56-0.79) LOC647946(84.3k) 
rs71540757 7 16,653,094 A/G Imp 0.96 6.16E-06 1.81 (1.40-2.34) ANKMY2 
rs2159129 19 29,049,808 C/T Imp 0.98 7.09E-06 1.52 (1.27-1.83)  
rs10510254 3 3,279,498 C/T Imp 0.99 7.15E-06 0.50 (0.37-0.68) CRBN(58.1k) 
rs9815296 3 178,152,351 T/G Imp 0.99 7.91E-06 2.20 (1.55-3.13)  
rs7556080 1 154,638,826 A/G Geno 0.98 8.45E-06 1.53 (1.27-1.85) ADAR(38.4k) 
rs4612821 11 134,444,050 T/C Imp 0.97 9.21E-06 0.64 (0.53-0.78)  
rs3779323 7 77,684,897 C/T Geno 0.99 9.93E-06 0.66 (0.55-0.79) MAGI2 
CHR: Chromosome, POS: Physical position NCBI built 37.3 hg19, Allele A1: Minor allele, Allele A2: Major 
allele, Imp: SNP imputed, Geno: SNP genotyped, Info: SNPtest info value, Gene: Gene nearby the 
associated SNP, distance in brackets. The top-ranked SNP was represented in regions with several single 
marker association signals exceeding TDT P < 1.0 × 10
-5
 (*). 
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GWAS meta-analysis of GGE 
The results of GWAS meta-analysis of 1,523 GGE cases, 2,454 controls and 566 GGE 
trios with 4,224,196 overlapping SNPs are shown in Table 3-3 and Figure 3-3. In 
total, seven SNPs showed genome-wide significance (P < 5.0 × 10-8). The top-ranked 
association was found in an intergenic region on chromosome 2p16.1 (rs35577149, 
chr2:57931347, meta-analysis P = 1.65 × 10-8, OR[C] = 0.78, 95% CI 0.71 – 0.86). In 
addition, 41 SNPs reached the threshold for suggestive association (LMM P < 1.0 × 
10-5). All meta-analysis P-values were corrected for genomic inflation (λ = 1.021, see 
QQ-plot in Suppl. 6.3.1). 
SNP markers with observed genome-wide significance were plotted with 
LocusZoom for regional view and to indicate the LD of neighboring SNPs with 
reference to the SNP with the most significant P-value. The top-ranked SNP 
rs35577149 is in strong LD with six significant SNPs at chromosome 2p16.1 (Figure 
3-4). 
 
Figure 3-2 | Manhattan plot of genome-wide association in 566 GGE trios. The x–axis shows the genomic 
position of SNP markers on chromosomes 1 to 22 (NCBI built 37.3, hg19), the y-axis shows the negative 
log10 of the single marker P-value of the Transmission Disequilibrium Test (TDT) association statistic. The 
blue line represents the threshold for a suggestive association with P < 1.0 ×10
-5
, the red line for significant 
association with P < 5.0 × 10
-8
. 
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Figure 3-3 | Manhattan plot of genome-wide association meta-analysis in 1,523 GGE cases, 2,454 controls 
and 566 GGE trios. The x–axis shows the genomic position of SNP markers on chromosomes 1 to 22 (NCBI 
built 37.3, hg19), the y-axis shows the negative log10 of the meta P-value per SNP. The blue line 
represents the threshold for a suggestive association with P ≤ 1.0 × 10
-5
, the red line for significant 
association with p ≤ 5.0 × 10
-8
. 
Table 3-3 | Genome-wide association meta-analysis results of P < 10
-5
 in GGE 
SNP CHR POS Allele 
A1/A2 
LMM P TDT P Meta P ORmeta 
(95% CI) 
Gene 
rs35577149* 2 57,931,347 C/T 2.60E-07 0.01 1.65E-08 0.79 (0.73-0.86)  
rs6999304* 8 89,590,027 G/C 3.06E-05 0.01 1.77E-06 1.33 (1.17-1.51)  
rs12059546* 1 239,970,097 G/A 4.75E-05 0.01 2.31E-06 1.29 (1.17-1.43) CHRM3 
rs62059804* 17 7,453,505 A/C 3.70E-05 0.02 2.63E-06 0.79 (0.72-0.87) TNFSF12 
rs17734302* 7 21,092,494 A/G 5.60E-04 3.66E-04 2.99E-06 0.78 (0.70-0.87)  
rs17779783* 20 2,121,659 C/T 3.88E-05 0.04 4.95E-06 1.55 (1.28-1.88) STK35 
rs3101626 15 27,820,990 C/T 2.57E-04 5.61E-03 7.42E-06 1.27 (1.14-1.41) GABRG3(42.9k) 
rs113403571* 17 46,097,524 G/A 1.52E-05 0.14 7.81E-06 0.76 (0.68-0.84) COPZ2(6.0k) 
CHR: Chromosome; POS: Physical position NCBI built 37.3 hg19, Allele A1: Minor allele, Allele A2: Major 
allele, Gene: Gene nearby the associated SNP, distance in brackets. The top-ranked SNP was 
represented in regions with several single marker association signals exceeding Meta P < 1.0 × 10
-5
 (*). 
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3.1.2 Genome-wide association and meta-analysis of GAE patients 
GWAS analysis of the subgroup of patients with GAE included two datasets: i) 705 
European GAE cases, 2,454 German controls, and ii) 317 European parent-offspring 
trios affected by GAE. The results of both association studies were combined into a 
genome-wide meta-analysis. The case-control data set in our study is equivalent to 
the Stage-1 data cohort of a previously published GWAS (EPICURE Consortium et al., 
2012a). 
Case-control GWAS of GAE 
Genome-wide association analysis with 5,564,397 SNPs was performed using 705 
GAE patients and 2,454 controls. No SNP was observed with a P-value lower than 
the threshold for significance. Suggestive association was detected in 86 SNPs (Table 
3-4, Figure 3-5). Lowest P-value was found at 2q22.3 (rs75917352, 
chr2:145370978, LMM P = 3.54× 10-7, OR[T] = 0.63, 95% CI 0.53 – 0.76), with 
 
Figure 3-4 | Regional detail plot of the –log10 of LMM P-value of GGE for SNP rs35577149 on chromosome 
2p16.1, presenting genes and LD of neighboring SNPs close to detected association. SNP color code is 
complied with r
2
 value referring to rs35577149, physical position in NCBI built 37.3, hg19. 
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LOC100131409 as the nearest gene locus (54.4k apart). Correction of P-values for 
genomic inflation was not required (λ = 0.990, see QQ-plot in Suppl. 6.3.2). 
 
 
  
 
Figure 3-5 | Manhattan plot of genome-wide association in 705 GAE cases versus 2,454 controls. The x–
axis shows the genomic position of SNP markers on chromosomes 1 to 22 (NCBI built 37.3, hg19), the y-
axis shows the negative log10 of the LMM P-value per SNP. The blue line represents the threshold for a 
suggestive association with P ≤ 1.0 × 10
-5
, the red line for significant association with p ≤ 5.0 × 10
-8
. 
Table 3-4 | Genome-wide association results of LMM P < 10
-5
 in GAE 
SNP CHR POS 
Allele 
A1/A2 Source Info LMM P 
OR 
(95% CI) Gene 
rs75917352* 2 145,370,978 T/G Imp 0.99 3.54E-07 0.63 (0.53-0.76) LOC100131409(54.4k) 
rs6683622* 1 186,886,134 A/G Imp 1.00 3.58E-06 1.34 (1.18-1.53) PLA2G4A 
rs13030122* 2 38,759,473 A/G Imp 0.98 4.47E-06 0.69 (0.60-0.81) HNRPLL(30.9k) 
rs12904369* 15 97,335,674 A/C Geno 1.00 4.70E-06 0.73 (0.64-0.83) SPATA8(6.8k) 
8-2706322 8 2,706,322 C/T Imp 0.92 6.83E-06 1.67 (1.31-2.15) CSMD1(86.6k) 
rs17394336 22 26,665,807 A/G Imp 0.98 6.85E-06 1.51 (1.25-1.82) #SEZ6L# 
rs9948832* 18 25,857,441 A/C Imp 1.00 6.93E-06 1.37 (1.20-1.57) CDH2(100.0k) 
rs1859161 4 106,042,692 T/C Geno 1.00 7.70E-06 0.63 (0.51-0.77) TET2(25.2k) 
CHR: Chromosome, POS: Physical position NCBI built 37.3 hg19, Allele A1: Minor allele, Allele A2: Major 
allele, Imp: SNP imputed, Geno: SNP genotyped, Info: SNPtest info value, Gene: Gene nearby the 
associated SNP, distance in brackets. The top-ranked SNP was represented in regions with several single 
marker association signals exceeding LMM P < 1.0 × 10
-5
 (*). 
3 | Results 
44 
Family-based GWAS of GAE 
The family-based GWAS included 317 affected trios and 5,098,822 SNPs in the GAE 
subgroup (Table 3-5, Figure 3-6). No SNP with significant association was identified, 
but 19 SNPs showed suggestive association. The most prominent result was 
detected on chromosome 2q14.1 (rs6721192, chr2:116,483,984, TDT P = 1.42 × 10-
6, OR[T] = 0.56, 95% CI 0.44 – 0.71), in the genomic sequence of the gene DPP10. All 
P-values were corrected for genomic inflation (λ = 1.011, see QQ-plot in Suppl. 
6.3.2). 
 
Table 3-5 | Genome-wide association results of TDT P < 10
-5
 in GAE 
SNP CHR POS Allele 
A1/A2 
Sourc
e 
Info TDT P OR 
(95% CI) 
Gene 
rs6721192* 2 116,483,984 T/C Imp 0.99 1.42E-06 0.56 (0.44-0.71) DPP10 
rs12449765 17 32,840,267 G/A Geno 1.00 1.80E-06 2.28 (1.61-3.23) C17orf102(60.9k) 
rs114488716 5 160,281,684 G/A Imp 0.99 3.03E-06 0.28 (0.16-0.49) ATP10B(2.5k) 
rs37277* 7 41,345,488 G/A Geno 1.00 3.77E-06 0.46 (0.33-0.65)  
rs6735372* 2 60,538,864 A/G Imp 0.99 4.37E-06 2.00 (1.48-2.70)  
rs1417251 1 102,920,751 T/G Imp 0.99 5.19E-06 3.00 (1.83-4.92)  
rs10484968* 6 120,396,111 T/C Geno 1.00 5.67E-06 7.75 (2.74-21.95)  
rs4903677 14 78,425,068 G/C Geno 1.00 7.93E-06 2.10 (1.51-2.92) ADCK1(24.8k) 
rs72813644* 17 14,708,060 A/T Imp 0.99 8.48E-06 0.38 (0.25-0.59) FLJ45831(24.6k) 
rs60782598 5 27,150,498 A/G Impd 0.99 9.85E-06 0.55 (0.42-0.72)  
CHR: Chromosome, POS: Physical position NCBI built 37.3 hg19, Allele A1: Minor allele, Allele A2: Major 
allele, Imp: SNP imputed, Geno: SNP genotyped, Info: SNPtest info value, Gene: Gene nearby the 
associated SNP, distance in brackets. The top-ranked SNP was represented in regions with several single 
marker association signals exceeding TDT P < 1.0 × 10
-5
 (*). 
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GWAS meta-analysis of GAE 
Results of meta-analysis of 705 IAE cases, 2,454 controls and 317 IAE trios, and 
4,224,597 overlapping SNPs are shown in Table 3-6, Figure 3-7. No SNP reached 
threshold for genome-wide significance, but 64 SNPs reached the threshold for 
suggestive association. The highest peak was observed on chromosome 2q22.3 
(rs75917352, chr2:145,370,978, meta P = 1.41 × 10-7, OR[T] = 0.67, 95% CI 0.58 – 
0.79), the closest gene ZEB2 93.1 kb away. All P-values were corrected for genomic 
inflation (λ = 1.009, see QQ-plot in Suppl. 6.3.2). 
 
Figure 3-6 | Manhattan plot of genome-wide association in 317 GAE trios. The x–axis shows the genomic 
position of SNP markers on chromosomes 1 to 22 (NCBI built 37.3, hg19), the y-axis shows the negative 
log10 of the single marker P-value of the TDT association statistic. The blue line represents the threshold 
for a suggestive association with P < 1.0 ×10
-5
, the red line for significant association with P < 5.0 × 10
-8
. 
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Figure 3-7 | Manhattan plot of genome-wide association meta-analysis in 705 GAE cases, 2,454 controls 
and 317 GAE trios; the x–axis shows the genomic position of SNP markers on chromosomes 1 to 22 (NCBI 
built 37.3, hg19), the y-axis shows the negative log10 of the meta P-value per SNP. The blue line 
represents the threshold for a suggestive association with P ≤ 1.0 × 10
-5
, the red line for significant 
association with p ≤ 5.0 × 10
-8
. 
Table 3-6 | Genome-wide association meta-analysis results of P < 10
-5
 in GAE 
SNP CHR POS Allele 
A1/A2 
LMM P TDT P Meta P ORmeta 
(95% CI) 
Gene 
rs75917352* 2 145,370,978 T/G 3.54E-07 0.12 1.41E-07 0.67 (0.58-0.79) ZEB2(93.1k) 
rs11585765* 1 226,704,825 T/C 7.31E-06 0.12 2.60E-06 0.75 (0.64-0.84) C1orf95(31.7k) 
rs9953249 18 74,380,851 A/G 1.29E-05 0.12 4.36E-06 0.70 (1.17-1.47) FLJ44881(21.3k) 
rs77859246* 11 122,976,828 A/T 2.36E-04 3.12E-03 5.58E-06 0.70 (0.60-0.82) ASAM 
rs7519192* 1 186,862,419 G/A 4.08E-06 0.40 5.85E-06 0.75 (1.15-1.45) PLA2G4A 
rs11682175* 2 57,987,593 C/T 3.43E-05 0.06 5.93E-06 0.75 (0.69-0.85)  
rs1418029 20 2,060,151 A/G 2.07E-05 0.12 6.77E-06 0.75 (1.31-1.98) STK35(23.4k) 
rs1519309 4 187,015,089 T/C 5.64E-05 0.04 6.79E-06 0.75 (1.14-1.43) TLR3(8.8k) 
rs57074415* 6 47,661,859 T/C 1.24E-03 1.66E-04 8.00E-06 0.72 (0.65-0.84) GPR115(4.4k) 
rs37277 7 41,345,488 G/A 4.85E-03 3.77E-03 9.06E-06 0.67 (0.61-0.82)  
rs17394336 22 26,665,807 A/G 6.85E-06 0.40 9.32E-06 0.75 (1.21-1.70) SEZ6L 
rs2215503* 18 25,890,637 G/A 1.62E-04 0.01 9.62E-06 1.35 (0.70-0.87)  
CHR: Chromosome, POS: Physical position NCBI built 37.3 hg19, Allele A1: Minor allele, Allele A2: Major 
allele, Gene: Gene nearby the associated SNP, distance in brackets. The top-ranked SNP was represented 
in regions with several single marker association signals exceeding Meta P < 1.0 × 10
-5
 (*). 
Results | 3 
47 
3.1.3 Genome-wide association and meta-analysis of JME patients 
Genome-wide association was tested in the JME subgroup with 579 European JME 
cases, 2,454 German controls and 157 European parent-offspring trios affected by 
JME. The results of both association studies were combined into a genome-wide 
meta-analysis. The case-control data set in our study is equivalent to the Stage-1 
data cohort of a previously published GWAS (EPICURE Consortium et al., 2012a). 
Case-control GWAS of JME 
The case-control based genome-wide association analysis in the JME subgroup was 
performed using 579 JME patients and 2,454 controls among 5,563,947 SNPs. No 
SNP reached the threshold for genome-wide significance, 64 SNPs reached the 
threshold for suggestive association (Table 3-7, Figure 3-8). The lowest P-value was 
observed at chromosome 1q43 (rs12059546, chr1:239970097, LMM P = 1.97 × 10-7, 
OR[G] = 1.53, 95% CI 1.32 – 1.79), within gene CHRM3. Genomic inflation factor was 
< 1 and therefore no genomic correction applied (λ = 0.999, see QQ-plot in Suppl. 
6.3.3). 
3 | Results 
48 
 
 
 
Figure 3-8 | Manhattan plot of genome-wide association in 579 JME cases versus 2,454 controls; the x–
axis shows the genomic position of SNP markers on chromosomes 1 to 22 (NCBI built 37.3, hg19), the y-
axis shows the negative log10 of the single marker P-value of the LMM association statistic. The blue line 
represents the threshold for a suggestive association with P < 1.0 ×10
-5
, the red line for significant 
association with P < 5.0 × 10
-8
. 
Table 3-7 | Genome-wide association results of LMM P < 10
-5
 in JME 
SNP CHR POS Allele 
A1/A2 
Source Info LMM P OR 
(95% CI) 
Gene 
rs12059546 1 239,970,097 G/A Geno 1.00 1.97E-07 1.53 (1.32-1.79) CHRM3 
rs25833 5 66,175,175 T/C Imp 0.97 3.00E-07 1.38 (1.20-1.58) MAST4 
rs3125293 1 212,763,530 G/T Imp 0.97 2.48E-06 1.35 (1.18-1.55) ATF3 
rs34591495 3 48,644,202 T/C Imp 0.95 2.91E-06 1.49 (1.24-1.79) UQCRC1 
rs13264787 8 128,631,805 G/T Imp 0.94 3.28E-06 0.67 (0.56-0.80)  
rs17669194 13 34,267,584 T/C Geno 1.00 4.35E-06 1.49 (1.26-1.77)  
18-20199084 18 20,199,084 C/A Imp 0.92 6.07E-06 1.31 (1.15-1.49)  
rs6913416 6 157,454,046 C/T Imp 0.98 6.28E-06 1.47 (1.21-1.79) ARID1B 
rs74621069 20 41,823,592 T/C Imp 0.99 7.21E-06 2.02 (1.54-2.65) PTPRT(5.0k) 
rs11151793 18 70,422,507 C/T Imp 1.00 7.25E-06 1.46 (1.26-1.69) NETO1 
rs12963674 18 55,978,595 T/G Geno 1.00 7.47E-06 1.87 (1.46-2.40) NEDD4L 
rs79608766 20 41,82,3630 T/C Imp 0.98 7.50E-06 2.02 (1.54-2.66) PTPRT(5.1k) 
rs6932561 6 14,076,716 T/C Imp 1.00 9.36E-06 0.76 (0.66-0.86) CD83(41.1k) 
rs6039250 20 8,729,333 C/T Imp 0.99 9.78E-06 0.67 (0.54-0.81) PLCB1 
CHR: Chromosome, POS: Physical position NCBI built 37.3 hg19, Allele A1: Minor allele, Allele A2: Major 
allele, Imp: SNP imputed, Geno: SNP genotyped, Info: SNPtest info value, Gene: Gene nearby the 
associated SNP, distance in brackets. The top-ranked SNP was represented in regions with several single 
marker association signals exceeding LMM P < 1.0 × 10
-5
 (*). 
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Family-based GWAS of JME 
Genome-wide association analysis in JME families included 157 parent-offspring 
trios affected by JME, using 5,098,752 SNPs. Only one SNP reached the suggestive 
threshold (top five results shown in Table 3-8, Figure 3-9). The suggestive p-value 
was reported for chromosome 4q28.1 (rs313047, chr7:86192385, TDT P = 6.61 × 
10-6, OR[T] = 2.26, 95% CI 1.58 – 3.23) in a non-coding region, with no gene as close 
as 100 kb. Correction for genomic inflation was required and applied to all p-values 
(λ = 1.026, see QQ-plot in Suppl. 6.3.3). 
 
 
 
Figure 3-9 | Manhattan plot of genome-wide association in 157 JME trios. The x–axis shows the genomic 
position of SNP markers on chromosomes 1 to 22 (NCBI built 37.3, hg19), the y-axis shows the negative 
log10 of the single marker P-value of the TDT association statistic. The blue line represents the threshold 
for a suggestive association with P < 1.0 ×10
-5
, the red line for significant association with P < 5.0 × 10
-8
. 
Table 3-8 | Top-ranked GWAS TDT results for JME 
SNP CHR POS 
Allele 
A1/A2 Source Info TDT P 
OR 
(95% CI) Gene 
rs313047* 4 127,626,494 T/C Imp 0.98 6.61E-06 2.26 (1.58-3.23)  
rs12130711* 1 247,607,642 T/C Imp 0.98 1.02E-05 0.46 (0.32-0.65) NLRP3 
rs66978760* 13 61,849,275 T/A Imp 0.92 1.26E-05 5.14 (2.29-11.56)  
rs131024* 22 49,174,763 T/G Imp 0.96 1.27E-05 0.45 (0.31-0.64) FAM19A5(27.0k) 
rs17719479 16 78,491,051 G/C Imp 0.95 1.82E-05 0.30 (0.17-0.53) WWOX 
CHR: Chromosome, POS: Physical position NCBI built 37.3 hg19, Allele A1: Minor allele, Allele A2: Major 
allele, Imp: SNP imputed, Geno: SNP genotyped, Info: SNPtest info value, Gene: Gene nearby the 
associated SNP, distance in brackets. The top-ranked SNP was represented in regions with several single 
marker association signals exceeding TDT P < 1.0 × 10
-5
 (*). 
3 | Results 
50 
GWAS meta-analysis of JME 
GWAS meta-analysis of 579 JME cases, 2,454 controls and 157 JME trios, was 
performed using 4,220,447 SNPs (Table 3-9, Figure 3-10). Five SNPs showed 
genome-wide significance, seven additional SNPs reached the threshold for 
suggestive association. The significant peak was observed on chromosome 1q43 
(rs12059546, chr1:239970097, meta-analysis P = 2.27 × 10-08, OR[G] = 1.53, 95% CI 
1.33 – 1.78), within the gene CHRM3. All P-values were corrected for genomic 
inflation (λ = 1.010, see QQ-plot in Suppl. 6.3.3). 
 
 
 
Figure 3-10 | Manhattan plot of genome-wide association meta-analysis in 579 JME cases, 2,454 controls 
and 157 JME trios. The x–axis shows the genomic position of SNP markers on chromosomes 1 to 22 (NCBI 
built 37.3, hg19), the y-axis shows the negative log10 of the meta P-value per SNP. The blue line 
represents the threshold for a suggestive association with P ≤ 1.0 × 10
-5
, the red line for significant 
association with p ≤ 5.0 × 10
-8
. 
Table 3-9 | Genome-wide association meta-analysis results of P < 10
-5
 in JME 
SNP CHR POS 
Allele 
A1/A2 LMM P TDT P Meta P 
ORmeta 
(95% CI) Gene 
rs12059546* 1 239,970,097 G/A 1.97E-07 0.03 2.27E-08 1.53 (1.33-1.77) CHRM3 
rs72750824 9 112,380,046 G/C 3.26E-05 0.01 2.66E-06 1.66 (1.34-2.05) PALM2(23.0k) 
rs17669194 13 34,267,584 T/C 4.35E-06 0.49 5.03E-06 1.45 (1.23-1.70)  
rs845742 5 109,002,085 A/C 6.31E-05 0.02 7.53E-06 0.71 (0.62-0.80) MAN2A1(23.1k) 
CHR: Chromosome, POS: Physical position NCBI built 37.3 hg19, Allele A1: Minor allele, Allele A2: Major 
allele, Gene: Gene nearby the associated SNP, distance in brackets. The top-ranked SNP was 
represented in regions with several single marker association signals exceeding Meta P < 1.0 × 10
-5
 (*). 
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SNP markers achieving genome-wide significance were plotted with LocusZoom for 
regional view and to show LD of neighboring SNPs. The top-ranked SNP rs12059546 
on chromosome 1q43 (Figure 3-11) was in tight LD with neighboring SNPs reaching 
significant and suggestive P-values. Several regions with increased recombination 
rate are close to the locus showing significance. 
 
  
 
Figure 3-11 | Regional detail plot of the –log10 of LMM P-value of JME subgroup for SNP rs12059546 on 
chromosome 1q43, presenting genes and LD of neighboring SNPs close to detected association. SNP color 
code is complied with r
2
 value referring to rs35577149, physical position in NCBI built 37.3, hg19. 
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3.2 Analysis of recurrent microdeletions associated with GGE 
Six recurrent microdeletions that have previously been reported in neuropsychiatric 
disorders including autism, intellectual disability and schizophrenia, were evaluated 
for contributing to risk of GGE (Table 2-2). In total, a case-control sample cohort of 
1,495 European GGE patients and 5,374 German controls in addition to 566 
European parent-offspring trios affected by GGE were selected for microdeletion 
analysis. Parts of this study have previously been published (Helbig et al., 2009; de 
Kovel et al., 2010). 
Recurrent microdeletions in GGE 
In total, we detected deletions at the six candidate loci (1q21.1, 15q11.2, 15q13, 
16p11.2, 16p13.11 and 22q11.2) in 56 (2.7%) out of 2,061 GGE cases and 22 (0.4%) 
out of 5,940 controls (OR = 7.51, 95% CI 4.50 – 12.95, χ2 = 84.88, 1 degree of 
freedom (df), p < 2.20 × 10−16) (Figure 3-12, Table 3-10). Significant associations 
(nominal P < 0.0083) with GGE were found for the recurrent microdeletions at 
15q11.2, 15q13, 16p11.2, 16p13.11 and 22q11.2 (Table 3-10). 
Microdeletions at 1q21.1 were observed in 3 (0.1%) out of 2,061 GGE cases and in 2 
(< 0.1%) out of 5,940 controls (OR = 4.33, 95% CI 0.50 – 51.82, Fisher's exact p = 
0.11) (Table 3-10, Figure 3-12). An association of GGE with microdeletions at 
15q11.2 was detected, which was found in 21 (1.0%) GGE cases and in 17 (0.3%) 
controls (OR = 3.59, 95% CI 1.80 – 7.25, χ2 = 15.86, 1 df, p = 1.12 × 10−4) (Table 3-6, 
Figure 3-13). The strongest association of microdeletions with GGE was identified at 
site 15q13.3, with deletions in 14 (0.7%) GGE cases and none in controls (Fisher's 
exact P = 5.48× 10−9) (Table 3-6, Figure 3-14). Likewise, association with GGE was 
observed at 16p13.11 with microdeletions in 11 (0.5%) GGE cases and in 2 (< 0.1%) 
controls (OR = 15.93, 95% CI 3.47 – 147.89, Fisher's exact p = 1.48× 10−5) (Table 3-6, 
Figure 3-15). Microdeletions in 16p11.2 were observed in 5 (0.2%) GGE cases and in 
1 (< 0.1%) control (OR = 11.54, 95% CI 1.41 – 567.06, Fisher's exact p = 0.02) (Table 
3-6, Figure 3-16). At 22q11.2, microdeletions were identified in 3 (0.1%) out of 
2,061 GGE cases and in none of 5,940 controls (Fisher's exact p = 0.02) (Table 3-6, 
Figure 3-17).  
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Figure 3-13 | Recurrent microdeletions at 15q11.2. Blue bars: Deletions in GGE patients, green bars: 
Deletions in controls and untransmitted deletions in trio pseudocontrols (*), grey bar: reported target 
region of the 15q11.2 microdeletion, SNP6: Sample genotyped with Affymetrix SNP6.0 array, AX: Sample 
genotyped with Affymetrix Axiom array. Produced with the University of California, Santa Cruz Genome 
Browser, positions in NCBI built 37.3, hg19 (http://www.genome.ucsc.edu). 
 
Figure 3-12 | Recurrent microdeletions at 1q21.1. Blue bars: Deletions in GGE patients, green bars: 
Deletions in controls and untransmitted deletions in trio pseudocontrols (*), grey bar: reported target 
region of the 1q21.1 microdeletion, SNP6: Sample genotyped with Affymetrix SNP6.0 array, AX: Sample 
genotyped with Affymetrix Axiom array. Produced with the University of California, Santa Cruz Genome 
Browser , positions in NCBI built 37.3, hg19 (http://www.genome.ucsc.edu). 
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Figure 3-15 | Recurrent microdeletions at 16p13.11. Blue bars: Deletions in GGE patients, green bars: 
Deletions in controls and untransmitted deletions in trio pseudocontrols (*), grey bar: reported target 
region of the 16p13.11 microdeletion, SNP6: Sample genotyped with Affymetrix SNP6.0 array, AX: Sample 
genotyped with Affymetrix Axiom array. Produced with the University of California, Santa Cruz Genome 
Browser, positions in NCBI built 37.3, hg19 (http://www.genome.ucsc.edu). 
 
Figure 3-14 | Recurrent microdeletions at 15q13.3. Blue bars: Deletions in GGE patients, grey bar: 
reported target region of the 15q13.3 microdeletion, SNP6: Sample genotyped with Affymetrix SNP6.0 
array, AX: Sample genotyped with Affymetrix Axiom array. Produced with the University of California, 
Santa Cruz Genome Browser, positions in NCBI built 37.3, hg19 (http://www.genome.ucsc.edu). 
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Familial segregation analysis 
DNA samples from both parents were available from 31 out of 56 patients with 
identified microdeletions (Figure 3-20). For segregation analysis, all available family 
members were typed by quantitative PCR and/or aCGH. In summary, 20 out of 31 
microdeletions were inherited, with 12 maternal and 9 paternal transmissions. Ten 
de novo deletions were identified in GGE patients (Figure 3-18, Suppl. 6-4). For 
1q21.1 microdeletions, one family with a de novo microdeletion was available for 
segregation analysis (Figure 3-18). DNA from both parents was available for 12 out 
 
Figure 3-17 | Recurrent microdeletions at 22q11.2. Blue bars: Deletions in GGE patients, grey bar: 
reported target region of the 22q11.2 microdeletion, SNP6: Sample genotyped with Affymetrix SNP6.0 
array, AX: Sample genotyped with Affymetrix Axiom array. Produced with the University of California, 
Santa Cruz Genome Browser, positions in NCBI built 37.3, hg19 (http://www.genome.ucsc.edu). 
 
Figure 3-16 | Recurrent microdeletions at 16p11.2. Blue bars: Deletions in GGE patients, green bars: 
Deletions in controls and untransmitted deletions in trio pseudocontrols (*), grey bar: reported target 
region of the 16p1.2 microdeletion, SNP6: Sample genotyped with Affymetrix SNP6.0 array, AX: Sample 
genotyped with Affymetrix Axiom array. Produced with the University of California, Santa Cruz Genome 
Browser, positions in NCBI built 37.3, hg19 (http://www.genome.ucsc.edu). 
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of 22 GGE patients carrying a 15q11.2 microdeletion, with one de novo, maternal and 
paternal inheritance in five patients each (Figure 3-18). Two trios were observed 
with unaffected parents carrying 15q11.2 microdeletions (one mother and one 
father) that were not transmitted to the child affected with GGE. In 7 out of 14 
patients with 15q13.3 microdeletions parental DNA was available. Paternal 
inheritance and maternal inheritances where found each in two out of eight 
transmissions, while de novo deletion events occurred in the remaining three 
families (Figure 3-18). DNA samples from both parents were available for 7 out of 11 
families carrying 16p13.11 microdeletions. De novo microdeletions were observed 
in two GGE patients. Maternal transmission was identified in three and paternal 
transmission two out of eight patients with inherited microdeletions. Parental DNA 
for segregation analysis of 16p11.2 microdeletions was available from three 
families, showing two de novo events and one maternal transmission. The family of 
22q11.2 microdeletion carrier was available for segregation analysis, displaying a de 
novo deletion in the affected child. 
In summary, recurrent microdeletions are inherited at approximately equal rates 
(11 maternal and 8 paternal transmissions). Ten microdeletions arose de novo. 
Notably, microdeletions at 15q11.2 showed a lower rate of de novo deletions (five 
maternal and paternal transmissions, two de novo events). For six families with de 
novo mutations, sufficient genotype data was available to differentiate the original 
paternal and maternal segment of the de novo deletion. In three families the 
maternal strand was deleted, three families showed deletion of the paternal strand. 
Overall families, 28 GGE deletion carriers shared their deletions with 4 affected and 
24 unaffected first-degree relatives. Eight first-degree relatives did not carry the 
deletion, although affected by GGE (Figure 3-20). These eight affected relatives 
without a deletion were all found in families exhibiting the 15q11.2 deletion. In 18 
out of 32 families, the transmitting parents were clinically unaffected (15q11.2 n = 9; 
15q13.3: n = 3; 16p13.11: n = 5; 16p11.2: n= 1). One father carrying a 15q13.3 
deletion was affected by GGE. Two fathers with 15q11.2 microdeletions were 
affected by CAE, one in addition to FS. For one sample with 16p13.11 microdeletion 
(204AE523, family XXIX), data of two additional siblings were available. All three are 
affected with GGE and inherited the microdeletion from their unaffected mother. 
3 | Results 
58 
 
Results | 3 
59 
 
 
Figure 3-18 | Familial segregation of the microdeletions at 1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p13.11 
and 22q11.2. Red symbols: individuals affected by IGE, a "x" denote the index-IGE patient. FS: febrile 
seizure, CAE: childhood absence epilepsy, JAE: juvenile absence epilepsy, JME: juvenile myoclonic epilepsy, 
EGTCS: epilepsy with generalized tonic–clonic seizures alone, EGMA= epilepsy with generalized tonic–
clonic seizures on awakening, TLE: temporal lobe epilepsy, copy number state: n: normal/two copies, DEL: 
deletion carrier. 
3 | Results 
60 
In general, cosegregation of the microdeletions was incomplete and did not follow 
an autosomal dominant pattern of inheritance, notably in the three largest families 
with 15q11.2 microdeletions (Figure 3-20; families II, III and VI). 
Penetrance estimations 
Penetrance calculations were performed as described before in CNVs associated 
with schizophrenia (Vassos et al., 2010). Confidence Intervals were calculated by the 
Clopper–Pearson exact tail area method (Rosenfeld et al., 2012). In our study, no 
deletions in controls were detected for microdeletions at 15q13.3 and 22q11.2. 
Incidence of 15q13.3 microdeletions in controls was acquired from combined data 
previously published with GGE (Dibbens et al., 2009), while no data for 
microdeletions in controls was available for 22q11.2 microdeletions. Penetrance 
estimations for the analyzed microdeletions ranged from 1.06% (95% CI 0.003 – 
0.038) at 15q11.2, to 12.49% (95% CI 0.070 – 0.201) at 15q13.3 (Table 3-11). 
 
Breakpoint validation 
The described recurrent microdeletions are reported to be flanked by highly 
homologous segmental duplications, promoting NAHR and therefore genomic 
rearrangements between reputed breakpoints. As breakpoint-estimation is difficult 
in regions with highly repetitive sequences, may vary between array platforms and 
due to limitations of calling algorithms, we used a customized oligonucleotide 
microarray to refine the breakpoints of the identified microdeletions (Suppl. 6-4). 
Breakpoints and microdeletion sizes estimated with aCGH were consistent with 
those maintained with the Affymetrix SNP6.0 array. 
Table 3-11 | Penetrance estimations of recurrent microdeletions 
Chr. Region Position Cases Controls Penetrance % 95% CI 
1q21.1 146.5-147.9 3/2061 2/5940 1.28 0.003-0.038 
15q11.2 22.75-23.2 21/2061 17/5940 1.06 0.007-0.017 
15q13.3 30.9-32.5 14/2061 8/50115* 12.49 0.070-0.201 
16p11.2 29.6-30.2 4/2061 1/5940 3.34 0.009-0.082 
16p13.11 14.8-16.4 12/2061 2/5940 4.93 0.0256-0.084 
22q11.2 19.2-22.2 1/2061 0/5940 - - 
* 15q13.3 microdeletions in controls from Dibbens et al., 2009; Position in NCBI built 37.3, hg 19. 
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Breakpoint positions from aCGH analysis were available for two samples genotyped 
with the Affymetrix Axiom® array, 276A and 157oB. Start and end point positions of 
detected microdeletions and LOH screening estimates differed from approximately 
250 kb to 670 kb. The LOH region at 15q11.2 in 157oB was about 400 kb smaller 
than the microdeletion detected with aCGH, the LOH region at 15q13.3 in 276A 
about 950kb smaller. Consequently, LOH screening as a prediction method for 
microdeletions is suitable for a defined core region, but lacks for precision to 
estimate limits of large microdeletions. 
Distribution of phenotypes among deletion carriers 
The distribution of microdeletions among GGE syndromes and sex of deletion 
carriers (CAE/GAE 52.5%, JME 28.8%, GTCS 18.6%, males 32.2%, females 67.8%) 
was equivalent to the distribution of sex and phenotypes in the complete sample 
cohort (CAE/GAE 48.1%, JME 35.8%, GTCS 16.1%, males 38.2%, females 61.8%). We 
observed no other feature, neither the dominance of a particular seizure type, nor 
the shift in age-of-onset, nor other neuropsychiatric disorders in family members 
carrying a deletion. 
3.3 Analysis of exon-ablating microdeletions associated with GGE 
3.3.1 Exon-ablating microdeletions in NRXN1 
In this candidate gene study, 1,569 unrelated GGE cases of European ancestry and 
6,201 German controls were analyzed for exon-disrupting/removing microdeletions 
in NRXN1. Results of this study has previously been published (Møller et al., 2013). 
A significant association of exon-ablating microdeletions was observed in 5 (0.3%) 
of 1,569 patients with GGE versus 2 (0.03%) of 6,201 control samples (P = 0.0049; 
OR = 9.91, 95% CI 1.92 – 51.12) (Figure 3-19, Suppl. 6.5). All five microdeletions in 
patients occurred in the 5´-terminal region of the genomic sequence of NRXN1; one 
including the promoter region and exon one, two including the promoter region and 
exons one and two, two microdeletions only including exon 2. Both exonic 
microdeletions in controls only included exon 2. Two patients with exonic 
microdeletions were affected by CAE; one by GAE, one by JME and one by EGTCS 
alone. 
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Family I was of German ancestry with three affected family members carrying a 200 
kb NRXN1 deletion (chr2:51,185,310-51,379,597, hg19) and the unaffected father 
(Figure 3-20). Both children (index patient L1748 and his sister) had CAE with FS. 
Additionally, the male patient showed moderate learning disability. The mother 
experienced episodes of short unresponsiveness in her childhood. Albeit no further 
diagnostics and no therapy were applied, we assess those events as a possible CAE. 
Family II was of German ancestry and consisted of three healthy and two children 
affected by GGE (Figure 3-20). Their mother was healthy and the father had type-1 
diabetes. A 480 kb NRXN1 deletion (chr2:50,979,977-51,453,231, hg19) was 
detected in all three affected children and in the father unaffected with neurologic 
disease. The index patient (KK2361) and her older sister were affected with CAE. 
Furthermore, the sister and one brother showed moderate ID, although the brother 
did not show any seizures. 
Family III was of Danish ancestry and consisted of a female with IAE (8P1844) and 
her healthy parents and sister; DNA of an additional unaffected brother was not 
available (Figure 3-20). A 600 kb NRXN1 deletion (chr2:51,080,429-51,682,854, 
hg19) was transmitted from the healthy father to the affected patient but not to her 
unaffected sister. A paternal half-sister had schizophrenia and Attention 
Deficit/Hyperactivity Disorder (ADHD), but was not available for testing. 
Family IV was a multiplex GGE family of German ancestry including three affected 
individuals, two sisters and their father (Figure 3-20). The mother had no history of 
epileptic seizures and her EEG was normal. One clinically unaffected brother and 
 
Figure 3-19 | Genomic positions of the seven exon-ablating NRXN1 deletions. Deletions in cases are 
represented by blue bars, deletions in controls by green bars. The figure was produced with the UCSC 
Genome Browser (http://www.genome.ucsc.edu), built hg19 based on the genomic positions from the 
Affymetrix Genome-Wide Human SNP Array 6.0 
Results | 3 
63 
one unaffected sister were not examined. The index patient (1696) was carrying a 
60-kb deletion (chr2:51,152,019-51,209,823, hg19) that occurred de novo in the 
proband and is affected by JME. Her sister is exhibiting JME as well. The father had 
partial epilepsy starting at the age of 57 years. 
Family V consisted of two affected siblings and their unaffected parents of Turkish 
origin (Figure 3-20). The proband (247oA) had an EGTCS with also photosensitive 
seizures and is carrying a de novo 110kb NRXN1 deletion (chr2:51,054,002-
51,163,990, hg19). His affected brother also had EGTCS, but without microdeletions 
in NRXN1. 
Segregation analysis was performed in all families of the five index cases carrying an 
exonic microdeletion in NRXN1 (Figure 3-20). We observed four multiplex families 
with more than one affected individual with GGE. In total, we observed eleven 
deletion carriers within all five families, seven of those with GGE. Deletions have 
 
Figure 3-20 | Familial segregation of exon-ablating NRXN1 deletions. Red symbols indicate persons 
affected by epilepsy, a "x" denote the index-IGE patient. CAE: childhood absences epilepsy; JAE: juvenile 
absence epilepsy; JME: juvenile myoclonic epilepsy; EGTCS: epilepsy with generalized tonic–clonic seizures 
alone; ID, intellectual disabilities; copy number state: n = normal/two copies; DEL = deletion carrier. 
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occurred de novo in two patients (families IV and V). One was inherited from an 
affected mother (family I), and two index patients inherited the deletion from an 
unaffected father (families II and III). 
In summary, a NRXN1 deletion was found in families I, II, and III in all affected family 
members, including one member with ID only. Since deletions were also present in 
two unaffected family members, penetrance is incomplete with an estimated 
probability of 78%. In families IV and V, the deletions are de novo mutations. 
Notably, affected family members without microdeletions in NRXN1 are present in 
those families. CNV penetrance based on Vassos et al., 2012 was estimated at 2.9 % 
(95% CI 0.001 – 0.007). 
3.3.2 Exon-ablating microdeletions in RBFOX1 
In this candidate gene study, 1,408 unrelated GGE cases of European ancestry and 
2,256 German controls were analyzed for deletions spanning or disrupting the 
genomic sequence of RBFOX1. Results of this study has previously been published 
(Lal et al., 2013). 
Exonic microdeletions were present in 5 (0.4%) of 1,408 GGE cases and none in 
2,256 controls (Fisher’s exact P = 0.0083). No exonic deletions were detected in 
controls. Deletions were 68 to 896 kb in size and all located in the 5’-terminal region 
of RBFOX1, encompassing the untranslated exons 1 - 4 (Figure 3-21, Suppl. 6.6). All 
by array identified CNVs in GGE patients were hemizygous and successfully 
validated by qPCR, DNA samples of the control subjects were not available for 
validation. 
From four out of five patients, DNA of family members was available for segregation 
analysis (Figure 3-22). In total, copy number state of the RBFOX1 was assessed in 20 
family members by qPCR. Twelve family members carried an exonic RBFOX1 
microdeletion (6 females, 6 males). All RBFOX1 deletions identified in the GGE index 
patients were inherited, no de novo events occurred. The deletions were transmitted 
five times maternally and one time paternally. Seven out of 12 deletion carriers were 
affected by GGE; five deletion carriers were clinically unaffected. Seven out of nine 
GGE patients investigated carried an exonic RBFOX1 deletion. Five of the seven 
Results | 3 
65 
deletion carriers were affected by typical absence epilepsies, and two carriers were 
affected by JME. 
In family I, exonic microdeletions in RBFOX1 were detected in all investigated family 
members with GGE. The index patient EG0369 was affected by CAE, delayed speech 
and learning disability. The deletion was transmitted maternally over two 
generations (mother with CAE and grandmother unaffected). DNA of an affected 
grand-grandfather was not available. The uncle of the index patient (EG0340) was 
affected by JME with absence seizures and GTCS, and was struck by unexpected 
sudden death at the age of 28. 
The exonic RBFOX1 microdeletions in family II were detected in the affected mother, 
the index patient and his unaffected brother. The father was unaffected and did not 
carry the deletion. Both mother and son are affected by IAE, while the index patients 
experienced FS and GTCS in addition. 
Family III consisted of an affected mother and two affected sons; the father and one 
additional sister are unaffected. The RBFOX1 deletion was transmitted by the 
unaffected father to the index patient (D07u680), affected by JME with GTCS. 
Magnetic resonance imaging scan showed structural abnormalities of the brain for 
bifrontal lesions in the patient due to a traumatic brain contusion occurring 16 years 
after the onset of the GGE. The mother and his brother were both affected by EGTCS 
but none of them carried a RBFOX1 microdeletion. The brother showed a pervasive 
developmental disorder, which is part of the diagnostic group of autism spectrum 
 
Figure 3-21 | Genomic positions of exon-ablating deletions in RBFOX1. Deletions in cases are represented 
by blue bars, deletions in controls by green bars. The figure was produced with the UCSC Genome Browser 
(http://www.genome.ucsc.edu), built hg19 based on the genomic positions from the Affymetrix Genome-
Wide Human SNP Array 6.0. 
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disorders (ASD). DNA of unaffected the sister was not available for testing. Vision 
impairment due to a strong myopia was present in the mother and all three siblings. 
In family IV, an exonic RBFOX1 microdeletion was transmitted maternally over three 
generations, with the male index patient (EG0395) as the only affected family 
member with CAE plus GTCS. 
Exonic microdeletions in RBFOX1 were found in seven affected and five unaffected 
family members, resulting in an estimated familial penetrance of 58%. Penetrance 
 
Figure 3-22 | Familial segregation of the exon-ablating RBFOX1 deletions. Red symbols: individuals 
affected by GGE, a "x" denote the index-IGE patient. Crossed individuals: Deceased, CAE: childhood 
absence epilepsy; JME: juvenile myoclonic epilepsy, EGTCS: epilepsy with generalized tonic–clonic seizures 
alone, FS: febrile seizures, ASD: autism spectrum disorder, copy number state: n = normal/two copies, 
DEL: deletion carrier. 
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estimation of exonic microdeletions based on Vassos et al., 2012 was not possible, 
because of insufficient control data. 
In summary, the present candidate gene CNV study of the neuron-specific splicing 
regulator gene RBFOX1 suggests that microdeletions affecting the untranslated 5'-
terminal RBFOX1 exons increase risk of common GGE syndromes. The present 
findings warrant further studies to replicate an involvement of RBFOX1 in the 
genetic predisposition of GGE syndromes and other common neurodevelopmental 
disorders and to elucidate the pathogenic mechanisms of epileptogenesis resulting 
from RBFOX1-mediated alterations of the splicing process of neuronal genes. 
 
4 | Discussion 
68 
4 Discussion 
4.1 Genome-wide association and meta-analysis 
The present GWAS meta-analysis displayed significant association at 2p16.1 with 
GGE and at 1q43 with JME (figures 3-3, 3-10). Despite a respectable size of the study 
sample, power calculations estimated a power of only 80% for meta-analysis to 
detect risk alleles with OR ≥ 1.34 in GGE (1,523 cases, 2545 controls and 566 trios), 
OR ≥ 1.47 in GAE (705 cases, 2545 controls and 317 trios) and with OR ≥ 1.56 in JME 
(579 cases, 2545 controls and 157 trios). Although power calculations for case-
control GWAS alone showed almost similar results (GGE OR ≥ 1.40, GAE OR ≥ 1.57, 
and JME OR ≥ 1.64), the detectable effect sizes of risk factors in trio-based analyses 
only were considerably higher (OR ≥ 1.87 in GGE, OR ≥ 2.35 in GAE, and OR ≥ 3.60 in 
JME trios). In comparison to the case-control sample cohort, the trio sample cohort 
was relatively small, contributing only 566 cases (for GGE; 317 for GAE and 157 for 
JME respectively) to the GWAS meta-analysis. Thus, statistical power was only 
increased marginally by combining both data sets, especially for the JME subgroup. 
We successfully strengthened the statistical evidence of previously reported 
associations at 1q43, 2p16.1, and 2q22.3 (EPICURE Consortium et al., 2012a), 
supporting their role as susceptibility factors for GGE. Further replication is 
required for novel association findings at 8q12.2, particularly with regard to the lack 
of a plausible candidate gene for epileptogenesis at this site. A locus at 17q21.32 
previously reported to be associated with GGE as well as a locus at 2q24.3 with 
former suggestive evidence for association with GGE (EPICURE Consortium et al., 
2012a) could not be confirmed in our meta-analysis. This demonstrates the dilemma 
of high variability in the outcome of GWAS, even if a part of the study cohort is 
overlapping between analyses. 
4.1.1 Significant association with GGE at 2p16.1 
Significant association was detected for GGE in the chromosomal region 2p16.1 
(Figure 3-3). The closest genes are VRK2 (vaccinia related kinase 2; ~340 kb away) 
and FANCL (Fanconi anemia, complementation group L; ~ 455 kb away). We 
therefore strengthened recently published results including our case-control cohort, 
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reporting association at 2p16.1 with GGE (rs13026414, P = 2.5 × 10−9, OR = 0.81) 
(EPICURE Consortium et al., 2012a). Previously, SNP rs2312147 close to VRK2 was 
associated with schizophrenia in a European (P = 1.9 × 10−9, OR = 1.09) (Steinberg et 
al., 2011) and an Asian-European meta-analysis (P = 2.21 × 10−8, OR = 1.11) (Li et al., 
2012). Regarding our own significant association signal at rs35577149, SNP 
rs2312147 is approximately 300 kb away and shows modest LD (r2 = 0.195, D' = 
0.660). VRK2 lies within the region of the 2p16.1-p15 deletion syndrome (OMIM 
#612513), causing developmental delay and/or mental retardation, autistic 
features, dysmorphic features, microcephaly, febrile seizures and intractable 
seizures with neonatal onset (Chandler et al., 2006; Rajcan-Separovic et al., 2007; 
Chabchoub et al., 2008; Félix et al., 2010). Consequently, genetic variation at the 
VRK2 locus may contribute to risk for GGE. 
4.1.2 Significant association with JME at 1q43 
Significant association was observed at chromosomal region 1q43, within the 
intronic region of the gene CHRM3 (cholinergic receptor, muscarinic 3; Figure 3-10). 
Accordingly, association has been reported previously at 1q43 (rs12059546, P = 2.3 
× 10−7, OR = 1.41) (EPICURE Consortium et al., 2012a). Despite mutations of genes 
encoding neuronal nicotinic acetylcholine receptor subunits are known to cause 
autosomal dominant nocturnal frontal lobe epilepsy (CHRNA4, CHRNB2) (Steinlein 
and Bertrand, 2010), no associations were found of genes encoding muscarinic 
acetylcholine receptors with epilepsy. CHRM3 confers differential cholinergic 
modulation to neurochemically distinct hippocampal basket cell subtypes (Rio et al., 
2010). After surgically removing sclerotic hippocampi of patients with refractory 
mesial temporal lobe epilepsy, hippocampal CA3 transcriptome signature revealed a 
cell-type specific expression of the M3 muscarinic acetylcholine receptor in distinct 
subtypes of hippocampal interneurons, providing a molecular mechanism for a 
differential cholinergic modulation of hippocampal circuitry (Ding et al., 2010; 
Bando et al., 2011). This may have an influence on synchronization and excitability 
of thalamocortical circuits and thereby seizure susceptibility, although M3 receptor 
knockout mice did not show an increase in pilocarpine-induced seizure activity 
(Bymaster et al., 2003). Most recently, a case study about a patient with ASD and a 
473 kb microdeletion affecting the CHRM3 gene has been reported (Petersen et al., 
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2013). Similarly, a microdeletion at 1q43 in a patient with mental retardation and 
short stature with three genes including CHRM3 was reported (Perrone et al., 2012). 
Those studies strongly suggest a possible link between M3-muscarinic receptor 
pathophysiology and a neurodevelopmental phenotype. 
4.1.3 Suggestive association with GGE at 8q12.2 
GWAS meta-analysis in GGE revealed evidence for suggestive association at 
chromosomal region 8q21.2. To our knowledge, this locus has not been reported to 
be associated with GGE or other epilepsies before. Notably, this locus is the only top-
hit from TDT analyses reaching suggestive level after meta-analysis. The association 
signal lies within the intronic region of FAM110B (family with sequence similarity 
110, member b). FAM110 proteins have been localized to centrosomes and 
accumulate at the microtubule organization center in interphase and at spindle 
poles in mitosis. Moreover, ectopic expression of FAM110B and FAM110C proteins 
impaired cell cycle progression in G1 phase (Hauge et al., 2007). Given the fact that 
the trio has a low power to detect low-risk effects and despite of potent candidate 
genes, this result requires further consideration. 
4.1.4 Suggestive association with GAE at 2q22.3 
Suggestive evidence for association with GAE was found in an intergenic region at 
2q22.2 (Figure 3-6), a locus that showed significant association in a previous study 
(rs10496964, P = 9.1 × 10−9, OR = 0.68) (EPICURE Consortium et al., 2012a). The 
suggestive association signal is approximately 93 kb away from ZEB2 (zinc finger e 
box-binding homeobox 2). Mutations in ZEB2 are responsible for the Mowat–Wilson 
syndrome (OMIM #235730), characterized by typical face, moderate-to-severe 
mental retardation, Hirschsprung disease, multiple congenital anomalies and a 
prevalence for epilepsy of about 70-75% (Garavelli et al., 2009; Cordelli et al., 2013). 
Recent studies in mice have revealed, that ZEB2 expression is required for 
generation and migration of cortical interneurons (McKinsey et al., 2013; van den 
Berghe et al., 2013). These interneurons are involved in phasing and synchronizing 
of neuronal activity (Cobb et al., 1995; Markram et al., 2004), suggesting a 
pathogenic mechanism that may operate in both epilepsy and Mowat–Wilson 
syndrome. 
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4.2 Recurrent microdeletions in GGE 
In the present study, we investigated the impact of six large recurrent 
microdeletions (at 1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p13.11 and 22q11.2), 
previously associated with neuropsychiatric disorders, to risk for common GGE 
syndromes (Ullmann et al., 2007; Sebat et al., 2007; Bassett et al., 2008; Brunetti-
Pierri et al., 2008; Sharp et al., 2008; Stefansson et al., 2008; Weiss et al., 2008; 
Kumar et al., 2008; Marshall et al., 2008; Mefford et al., 2008; Schizophrenia 
Consortium, 2008; Hannes et al., 2009; Kirov et al., 2009; Need et al., 2009). 
Combined analysis of all six recurrent microdeletions showed a significant 
enrichment of microdeletions in GGE patients on the contrary to unaffected controls 
and trio parents (P < 2.20 × 10-16). Microdeletions at 15q11.2, 15q13.3 and 16p13.11 
are significantly associated with GGE (15q11.2: P = 6.81 × 10-5, 15q13.3: P = 5.48 × 
10-9, 16p13.11 = 4.42 × 10-6). Nominal P-values of recurrent microdeletions at 
16p11.2 and 22q11.2 (both P-values = 0.02) would present further association, but 
after correction for multiple testing, significance level for association is not achieved 
(P < 0.0083). Still, our findings strengthen previous associations findings (de Kovel 
et al., 2010). 
The reported microdeletions comprise a number of promising candidate genes 
(Table 2-2). The gene HYDIN2 (chr1:146,310,551-146,334,209; hydrocephalus-
inducing, mouse, homolog of, 2) in the region of the 1q21.1 microdeletion is a 
homologue of HYDIN, which is expressed in the mouse brain in the developing 
choroid plexus. A frameshift mutation was reported to cause hydrocephalus in mice 
(Davy and Robinson, 2003). Accordingly, Brunetti-Pierri et al. proposed HYDIN2 as 
the most potent candidate gene in 1q21.2 microdeletions and microduplications 
(Brunetti-Pierri et al., 2008). The 15q11.2 microdeletion region includes the gene 
CYFIP1 (chr15: 15:22,892,683-23,003,602;cytoplasmic FMRP-interacting protein 1), 
that interacts with fragile X mental retardation protein (FMRP) as well as with the 
Rho GTPase Rac1, which is involved in regulating axonal and dendritic outgrowth 
and the development and maintenance of neuronal structures (Kobayashi et al., 
1998; Stefansson et al., 2008). Furthermore, haploinsufficiency of Cyfip1 was 
reported to produce fragile X-like phenotypes in mice. The gene CHRNA7 
(15:32,322,685-32,462,383; cholinergic receptor, neuronal nicotinic, alpha 
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polypeptide 7) in the 15q13.3 microdeletion is a prominent candidate gene in 
15q13.3 microdeletions associated with schizophrenia (Schizophrenia Consortium, 
2008; Stefansson et al., 2008) and epilepsy (Dibbens et al., 2009; Helbig et al., 2009; 
Mefford et al., 2010). The nicotinic acetylcholine receptors (nAChRs) are members of 
a superfamily of ligand-gated ion channels that mediate fast signal transmission at 
synapses and showed previous linkage with schizophrenia (Leonard and Freedman, 
2006). Recent findings of small, atypical 15q13.3 deletions encompassing only the 
CHRNA7 gene support the evidence, that CHRNA7 is responsible for the pathogenic 
effect of the 15q13.3 microdeletion (Liao et al., 2011; Hoppman-Chaney et al., 2013). 
Notably, homozygous microdeletions at 15q13.3 deletions result in a more severe 
phenotype including severe ID, epileptic encephalopathy and hypotonia (Endris et 
al., 2010; Spielmann et al., 2011). 
In the 16p11.2 microdeletion region, the gene PRRT2 (proline-rich transmembrane 
protein 2) was recently identified as a major cause for epilepsy with benign familial 
infantile seizures (Heron et al., 2012; Scheffer et al., 2012; Schubert et al., 2012). The 
gene NDE1 (16:15,737,123-15,820,209; nudE nuclear distribution E homolog 1) at 
chromosomal region 16p13.3 is strongly expressed in apical precursors in the 
ventricular zone and in the newborn neuronal population of the human embryonic 
brain. Mutations in NDE1 are believed to cause both severe failure of neurogenesis 
and deficiency in cortical lamination, resulting in lissencephaly and/or microcephaly 
(Bakircioglu et al., 2011). Lying in the microdeletion region 22q11.1, gene COMT 
(chr22:19,929,262 - 19,957,497; catechol-o-methyltransferase) has been associated 
with schizophrenia (Palmatier et al., 2004; Lee et al., 2005). COMT is one of the 
major mammalian enzymes involved in the metabolic degradation of 
catecholamines, catalyzing the transfer of a methyl group from S-adenosyl-
methionine (SAM) to a hydroxyl group on a catechol nucleus (e.g., dopamine, 
norepinephrine, or catechol estrogen) (Chen et al., 2004). An additional candidate 
gene at 22q11.1 is the SNP29 gene (chr22:21,213,292-21,245,502; synaptosomal-
associated protein, 29kDa) encoding a protein involved in multiple membrane 
trafficking steps. The SNAP29 protein binds to multiple syntaxins and is localized in 
intracellular membrane structures. Mutations in SNPA29 were found to cause the 
CEDNIK syndrome (OMIM #609528) (Sprecher et al., 2005; Fuchs-Telem et al., 
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2011), that shows some overlap of clinical features with 22q11.1 microdeletion 
carriers (Carvill and Mefford, 2013). 
Microdeletion carriers with GGE display a typical distribution of clinical features of 
GGE syndromes regarding seizure type and age of onset compared to all analyzed 
cases. The investigated microdeletions showed considerable variability in familial 
segregation and magnitude of epileptogenic effect. The microdeletion 15q13.3 
represents the most prominent risk factor, with an estimated OR > 50 based on an 
estimated frequency of about 0.02 % in the general population (Malhotra and Sebat, 
2012). According to more extensive analyses of CNVs in 517 individuals with 
various idiopathic, non-lesional epilepsies, 15q13.3 microdeletions are only 
reported in epilepsies with GGE syndromes exclusively, besides finding in other 
neurodevelopmental disorders (Mefford et al., 2010). 
Both 15q11.2 and 16p13.11 are more frequent in controls (0.29 % and 0.03 % 
respectively), thus showing lower OR (15q11.2 OR = 3.59, 16p13.3 =17.39). Due to 
the high frequency in controls of 15q11.2 microdeletions, 16p13.11 is the second 
strongest risk factor for IGE. Despite their lack of significance, high ORs are present 
in microdeletions at 16p11.2 (OR = 11.54) and 22q11.2 (OR > 50) as well. In 
particular, microdeletions in 22q11.2 are relatively rare with a frequency of < 0.2 % 
in GGE and 0.05 – 0.61 % in other neuropsychiatric disorders, not a single 22q11.2 
microdeletion was found in any of over 70,000 combined controls (Malhotra and 
Sebat, 2012). Consequently, microdeletions at 22q11.2 represent the CNV with the 
highest effect magnitude in neuropsychiatric disorders to date. 
Familial segregation of microdeletions was investigated where additional family 
members were available. Microdeletions at 15q11.2 in particular did not 
cosegregate with GGE in three large families (Figure 3-20). No other large families 
were available for segregation analysis. Consistent with two small families in which 
15q13.3 deletions segregated with unaffected family members in the present study, 
Dibbens and colleagues (Dibbens et al., 2009) found incomplete penetrance of the 
15q13.3 microdeletion in four out of seven pedigrees and three pedigrees included 
family members with GGE lacking the 15q13.3 deletion. Hence, 15q13.3 
microdeletions are not sufficient to express a disease phenotype on their own, which 
might also vary considerably depending on the genetic background and possible 
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environmental effects. De novo mutations were detected in all six recurrent 
microdeletions. Microdeletions at 15q11.2 showed a lower rate of de novo 
microdeletions compared to inherited events (ratio 1:5), while inheritance of the 
other microdeletions was distributed more equally (15q13 ratio 3:4, 16p11.2 2:1, 
16p13.11 3:5). In six families with de novo events, sufficient genotype data was 
available to identify the deleted strand, resulting in three maternal and three 
paternal mediated de novo microdeletions. The presence of de novo deletion events 
in conjunction with low population frequencies implicates purifying selection and 
thus may suggest a strong influence on the disease phenotype. 
Despite recent findings of a male-biased autosomal effect of 16p13.11 CNVs in 
neurodevelopmental disorders (Tropeano et al., 2013), the frequency of 16p13.11 
microdeletions in our study showed no male-biased effect. In contrast, 16p13.11 
microdeletions were twice as frequent in female cases, than in male cases (eight 
deletions in female GGE cases, four in male GGE patients). In controls, 16p13.11 
microdeletions were distributed equally. 
Remarkable phenotypic variability is observed in studies published for carriers of 
the six recurrent microdeletions (Table 2-2). Range of the phenotypic spectrum 
varies from apparently unaffected carriers to individuals with severe cognitive 
deficits, dysmorphisms and various neuropsychiatric features. The present epilepsy 
sample was ascertained by the GGE phenotype excluding those patients affected by 
major psychiatric and mental disorders. Moreover, carriers of microdeletions were 
re-evaluated for the presence of intellectual disability or other neuropsychiatric 
disorders. Notably, six patients show learning disability, legasthenia, mild 
developmental delay and intellectual disability (Suppl. 6.4), although it is unclear if 
those features are comorbidities of, or caused by GGE. However, it is unlikely that 
the excess of microdeletions found in our study is caused by unobserved 
comorbidity of neuropsychiatric disorders and GGE. 
Penetrance calculations of the reported microdeletions again show broad range of 
variability among our findings. In all analyzed microdeletions, penetrance is 
incomplete (except from 22q22.1, where no control data was available), ranging 
from 1.06 % (95% CI 0.01 – 0.02) for 15q11.2 to 12.49 % (95% CI 0.01 – 0.20) for 
15q13.3. The incomplete penetrance suggests that the impact of recurrent 
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microdeletions is modified by other genetic loci and/or environmental factors 
(Vassos et al., 2010), supporting an oligogenic model for epilepsy. Specifically, 
penetrance estimations may be useful for genetic counseling in families carrying 
those microdeletions, accounting more information to the understanding of 
developing epilepsy (Vassos et al., 2010; Rosenfeld et al., 2012). 
The possible mechanisms by which microdeletions mediate their pathogenic effects 
has recently been reviewed (Carvill and Mefford, 2013) but still remain in the very 
most cases. Haploinsufficiency of the deleted segment was considered the most 
likely mechanism for a long time (Itsara et al., 2009; Sharp, 2009; Heinzen et al., 
2010). Other genetic mechanisms such as imprinting, unmasking of different 
recessive allelic mutations on the intact homologous chromosomal segment and 
background genomic variation may contribute to the highly variable phenotypic 
expression (Sharp, 2009), despite other acquired or environmental factors. A “two-
hit” model of additional pathogenic CNVs contributing to a phenotype is conceivable 
as well (Girirajan et al., 2010, 2012). Recurrent microdeletions may confer a 
pleiotropic effect underlying various neuropsychiatric disorders. The complex 
interaction with additional factors might determine the specific phenotype. 
Although the microdeletions investigated are individually rare (<1%) in patients 
with GGE, they collectively account for a significant fraction of the genetic variance 
of common GGE syndromes. By identifying recurrent microdeletions at 15q11.2, 
15q13.3 and 16p13.11 as collectively significant genetic risk factors for GGE, our 
study provides new insights into the complex genetic predisposition of common 
epilepsies. Our present family study revealed a high percentage (>70%) of 
apparently unaffected parents transmitting the microdeletion to the affected child 
(Figure 3-20), suggesting that the microdeletion alone is not sufficient to cause an 
epilepsy phenotype in most cases. Likewise, unprecedented phenotypic 
heterogeneity has been found for seemingly identical microdeletions at 1q21.1, 
16p11.2, 15q13.3 and 22q11.2, ranging from severe genomic syndromes (e.g. 
22q11.2 microdeletion: DiGeorge syndrome, velocardiofacial syndrome) to a wide 
range of neuropsychiatric disorders (e.g. schizophrenia, intellectual disability and 
autism spectrum disorder), as well as in apparently unaffected individuals (for 
review see Mefford and Eichler, 2009). Together, our findings suggest the role of 
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neurodevelopmental processes in epileptogenesis. Given the frequency of recurrent 
microdeletions in various neuropsychiatric and neurodevelopmental disorders, 
identification of genetic and non-genetic factors determining phenotype–genotype 
relationship will be a major focus of future research. 
4.3 Exon-ablating microdeletions in NRXN1 and RBFOX1 
Candidate gene studies are well suited for detecting association in genes with 
common and more complex diseases, where the risk associated with any given 
candidate gene is expected to be relatively small (Risch and Merikangas, 1996; 
Collins et al., 1997). However, this approach is largely limited by its reliance on the a 
priori knowledge about the physiological, biochemical or functional aspects of 
possible candidates. 
The candidate genes NRXN1 and RBFOX1 were selected to investigate the 
contribution of exon-ablating microdeletions as risk factors to common GGE 
syndromes (see 1.5). Both studies underwent slightly different procedures for 
sample selection, due to a different starting point of the analysis, an accession of 
experience in handling large CNV data sets, different agreements with cooperation 
partners, and finally in different principle investigators who contributed diverging 
study approaches. The NRXN1 study sample underwent little sample selection, 
resulting in a large dataset of 1,569 GGE cases and 6,201 controls. Samples were 
only filtered by SNP QC criteria and no stringent PCA was applied. In contrast, 
selection of samples for the RBFOX1 study was relatively strict, resulting in 1,408 
GGE cases and 2,256 controls. Stringent PCA was performed and all samples with an 
excess of > 50 microdeletions were excluded from analysis. An additional control 
cohort was not available for screening. Nevertheless, results of both studies are still 
valid: All detected microdeletions were confirmed with at least one additional 
method. Procedures for CNV validation had an important influence for consideration 
of QC criteria: While validation of NRXN1 microdeletions were less complex, 
explanatory screenings showed that it was necessary to maintain a substantial 
amount of qPCR assays for validation of microdeletions in RBFOX1. Thus, different 
CNVs show a high variability in appearance, requiring careful and individual 
adjustment of the experimental design. 
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4.3.1 Exon-ablating microdeletions in NRXN1 
We investigated the influence of exon-disrupting/removing microdeletions of 
NRXN1 to increase the risk of common GGE syndromes. We detected significant 
association (p = 0.0049; OR = 9.91, 95% CI 1.92 – 51.12) with microdeletions of the 
promoter region, exon 1 and/or exon 2 of NRXN1 in 5 of 1,569 individuals with GGE 
(0.3), and in 2 of 6,201 controls (0.03%). Taking into account that our population-
based association analysis compared the frequency of NRXN1 deletions in GGE 
patients of European origin with that observed in German population controls 
(EPICURE Consortium et al., 2012a), it might be possible that confounding by 
population stratification might affect the present association result. However, this 
potential bias is unlikely to play a substantial role, considering that similar 
frequencies of exon-disrupting NRXN1 microdeletions have been reported in three 
cohorts of mainly Caucasian/European population controls (total: 3 of 7,700 = 
0.039%; 1/3,181 (Schizophrenia Consortium, 2008); 0 of 2,493 (Itsara et al., 2009); 
2 of 2,026 (Shaikh et al., 2009)). 
A remarkable phenotypic variability for individuals with NRXN1 deletions are 
reported, ranging from apparently unaffected carriers to individuals with severe 
cognitive deficits, ASD, and schizophrenia. The present epilepsy cohort was 
ascertained by the GGE phenotype, excluding those patients affected by severe ID 
and major psychiatric disorder such as ASD and schizophrenia (see 2.1). None of the 
index patients had any psychiatric disorder, and four of the five index patients had 
normal intelligence, whereas one had borderline intelligence. It is therefore unlikely 
that the excess of exonic NRXN1 deletions found in the present study is caused by 
unobserved comorbidity of IGE and psychiatric disorders or severe intellectual 
disability. 
The human neurexin gene family consists of the three genes NRXN1, NRXN2, and 
NRXN3. All three are subject to alternative promoter usage and extensive alternative 
splicing (Rowen et al., 2002). Two isoforms are known for each neurexin gene: A 
longer α-form that is transcribed from a promoter upstream of exon 1, and a short β-
form transcribed from an intragenic promoter. Expression of α-neurexins is 
essential for functional organization of synapses. Knockout mice lacking the α-
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neurexins die shortly after birth (Missler et al., 2003). All five exonic microdeletions 
identified in GGE patients lead to a disruption of the α-isoform of the gene. 
Segregation analysis of exonic NRXN1 microdeletions was analyzed in all five IGE 
families. The deletion occurred de novo in two patients, two were inherited from 
unaffected parents, and one was inherited from an affected parent. 
Several family members affected with epilepsy without and two unaffected 
individuals with the microdeletion are present. This suggests that exonic NRXN1 
microdeletions, like other microdeletions associated with GGE, are susceptibility 
variants, rather than highly penetrant mutations in these families. 
The exonic microdeletions in NRXN1 showed an incomplete penetrance of 78% in 
our three families with an inherited microdeletion. Compared to the previous 
reports of NRXN1 deletions in ID families, the penetrance in our families seems to be 
slightly higher (67% penetrance (Ching et al., 2010) and 50% penetrance (Gregor et 
al., 2011)). CNV penetrance estimations showed an incomplete penetrance of 2.9 % 
(95% CI 0.001-0.007). In comparison to our findings in recurrent microdeletions, 
this is in the middle range of our previous results, supporting the role of NRXN1 as a 
risk factor with moderate effect to GGE. 
In conclusion, we observed a significant excess of GGE patients carrying an exonic 
microdeletion of NRXN1 compared to controls. The deletion also acts in concert with 
other factors to modify neurologic phenotypes. Systematic screening for additional 
pathologic variants through array CGH studies or massive parallel sequencing 
studies may reveal additional modifying variants that explain the high variability of 
phenotypes. 
4.3.2 Exon-ablating microdeletions in RBFOX1 
The screening for exonic microdeletions in RBFOX1 revealed a significant excess of 
exonic deletions in patients with GGE compared with population controls. 
Microdeletions disrupting the exonic sequence of RBFOX1 were present in 5 (0.4%) 
of 1,408 GGE cases and none in 2,256 controls (Fisher’s exact P = 0.0083). In four of 
five microdeletion carriers, additional family members were available for 
segregation analysis. All of them were inherited, no de novo event was observed in 
families. Notably, none of the previously identified microdeletions associated with 
Discussion | 4 
79 
GGE at 15q11.2, 15q13.3, and 16p13.11 was found in the index patients carrying a 
RBFOX1 microdeletion. 
Microdeletions showed some variability in size, ranging from 68 to 896 kb. All were 
located in the 5’-terminal region of RBFOX1, encompassing the untranslated exons 
one to four (Figure 3-23). The RBFOX1 5’-terminal exons represent highly conserved 
genomic sequences and are predominantly expressed in brain, suggesting that the 
5’-terminal RBFOX1 region contains important regulatory elements (Damianov and 
Black, 2010). Accordingly to our study, structural genomic variations disrupted the 
5’-terminal exons of RBFOX1 have been previously reported in three single patients 
with neurodevelopmental disorders and epilepsy (Bhalla et al., 2004; Martin et al., 
2007b; Gallant et al., 2011). A significantly reduced RBFOX1 mRNA expression in 
lymphocytes was reported in a female with ASD, carrying a deletion of RBFOX1 exon 
1 due to a de novo translocation t(15p;16p) (Martin et al., 2007b). Equally, reduction 
in RBFOX1 mRNA expression might be expected in the members of family I in our 
study, carrying a large 896 kb microdeletion deleting RBFOX1 exons 1–2. This family 
is of particular interest because of the consistent cosegregation of the GGE trait with 
the RBFOX1 microdeletion (Figure 3-23). 
The functional mechanism of the four smaller microdeletions involving the RBFOX1 
5’-terminal exons 2–4, exon 1B and exon 4 remain elusive. Specifically, family III 
does not show cosegregation of GGE with the 163 kb spanning microdeletion 
affecting exon 4. This is consistent with heterogeneous cosegregation patterns, 
incomplete penetrance, and variable phenotypic expressivity observed for the 
recurrent microdeletions at 15q11.2, 15q13.3 and 16p13.11. 
Furthermore, we observed familial comorbidity with other neurodevelopmental 
disorders, such as learning disability and autism spectrum disorder, in RBFOX1 
families I and III. As subjects with severe intellectual disability or predominant 
neuropsychiatric disorders others than GGE were excluded from this study, 
comorbidity of generalized seizures with other neurodevelopmental disorders is 
expected to be more common among microdeletion carriers. 
Familial penetrance of exonic microdeletions in RBFOX1 showed an incomplete 
penetrance of 58%, being inherited in seven affected and five unaffected family 
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members, which is lower than in families with exonic NRXN1 microdeletions (78%). 
Similarly, the P-value of association with GGE is lower in NRXN1 (P = 0.0048) than in 
RBFOX1 (P = 0.0083). In summary, NRXN1 seems to have greater effect as a risk 
factor for GGE, although no exonic microdeletions of RBFOX1 were found in the 
control cohort. 
Considering the key role of the splicing regulator RBFOX1 in the control of neuronal 
excitation and seizure susceptibility (Gehman et al., 2011), the present findings 
suggest that rare microdeletions affecting the untranslated 5'-terminal RBFOX1 
exons increase risk of common GGE syndromes. Variable expressivity, incomplete 
penetrance, and heterogeneous cosegregation patterns suggest that RBFOX1 
deletions act as susceptibility factor in a genetically complex etiology where 
heterogeneous combinations of genetic factors determine the disease phenotype. 
4.4 Outlook 
The present study strengthens the evidence for three previously associated loci at 
1q43, 2p16.1, and 2q22.3 and yielded a novel locus with suggestive evidence for 
association at 8q12.2. This may serve as a starting point for the identification of new 
genes and/or factors involved in epileptogenesis. Definitely, further validation of the 
new 8q21.2 locus is required in an independent sample cohort to replicate our 
association finding. 
The same is true for the associated microdeletions at 15q11.2, 15q13.3, and 
16p13.11 and the exon-ablating microdeletions in NRXN1 and RBFOX1. The 
challenge for all association findings will be the identification of the causal 
variants/deletion targets and the revelation of the underlying mechanisms 
contributing to elevated risk of GGE. While approaches to the role of NRXN1 and 
RBFOX1 might suggest further functional analyses, the task for large recurrent 
microdeletions is to identify mutations in candidate genes and/or modifying factors 
contributing to GGE. A comprehensive CNV analysis of CNV burden and enrichment 
of possible disease-associated genes in CNVs of GGE patients may extend our 
understanding of CNV patterns in GGE syndromes. 
Next generation sequencing (NGS) techniques provide a promising tool for mutation 
screening in both candidate genes and regions at a large scale. Still, a careful 
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experimental design is necessary for this approach, given the high requirements in 
cost and DNA resources required for NGS up to date. Massively parallel sequencing 
of exomes or even whole genomes gives us the opportunity to obtain a massive 
amount of information from a single assay, which is as well the greatest pitfall of this 
development. The handling and utilization of datasets of fast growing size will be a 
challenge not less important than the validation and functional analysis of variations 
detected by NGS methods. 
With recent increase in CPU power and decrease of HDD memory costs, 
computationally intensive approaches like large scale meta-analysis on an 
international level and extensive SNP × SNP interaction studies are getting 
accomplishable. For example, a large multi-center meta-analysis of 9 GWAS of breast 
cancer identified 41 new susceptibility loci (Michailidou et al., 2013). Despite the 
promising reports, large-scale meta-analyses require the combination of several 
heterogeneous studies, and for conscientious data evaluation to assure valid results. 
Beside the identification of new variants and mutations, methylation and gene 
expression analysis might contribute additional important insights to 
epileptogenesis. A major problem in epilepsy is the lack of appropriate material, as 
brain tissue of epilepsy patients can only obtained from TLE patients that 
underwent resection surgery. In addition, DNA acquired from brain tissue showed a 
lower quality than other DNAs from blood samples used in an exploratory attempt. 
Especially calling of CNVs resulted in low quality data. To some degree, this accounts 
for inappropriate handling of tissue samples during and after surgery. However, 
brain tissue sample from TLE patients remains a rare source. A more promising 
approach is the reprogramming of somatic cells to create induced pluripotent stem 
cells (iPSC), which can be transformed into neurons. The performance of this 
method has been recently improved by advances in the understanding of the 
underlying mechanisms (Zhao et al., 2013). Analysis of neurons generated of iPSCs 
from patients with schizophrenia showed altered gene expression patterns of 
several genes and pathways, and a decrease in neuronal connectivity and neurite 
number (Brennand et al., 2011). 
Integrative analyses of data from GWAS and CNV analyses together with methylation 
and gene expression patterns may result in comprehensive findings on the basic 
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understanding of common GGE syndromes. All the obtained data may be put 
together into a systems biology approach that is more focused on underlying 
pathways and interactions of genetic and molecular factors than on the individual 
findings themselves. Systems biology is a promising trend in bioscience and epilepsy 
research that might result in a better understanding of disease and the development 
of new, maybe even multi-targeted drugs (Loeb, 2011; Margineanu, 2012). 
Animal models, especially on mice and rats, have been very important to study 
epilepsy. Until today, they give important insights in the mechanisms underlying 
epilepsy (Reid et al., 2012; Yalçın, 2012b). In addition, they provide the toolkit for 
the research and development of new therapy approaches. A recent example is the 
effect of apripiprazole, well-known for the treatment of e.g. schizophrenia, in a 
genetic rat model with absence epilepsy and mild-depression comorbidity (Russo et 
al., 2013). In the last few years, zebrafish (Danio rerio) are emerging as a promising 
model organism to study various brain disorders (reviewed in Stewart et al., 2012). 
Limitations of the zebrafish model are its size, more primitive behavior patterns and 
the evolutionary distance to humans. But as rodent models are more expensive to 
maintain and more difficult to genetically modify, and invertebrates lack a complex 
nervous system, zebrafish offer a reasonable compromise. In addition, both larvae 
and adult fish are available for analysis. Zebrafish may play an important role in 
detecting conserved mechanism and pathways in the etiology of GGE, as well as a 
powerful model for new therapy approaches. 
An integrative approach to identify novel epilepsy-associated genes and factors 
contributing to disease risk and phenotypic variability will increase our knowledge 
of the underlying mechanisms and the genetic architecture of common GGE 
syndromes. These findings may improve genetic counseling and prognosis for 
individuals affected by GGE and their families and may contribute to improve 
therapy of GGE patients. 
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6.1 Overview of seizure types 
 
TABLE 6-1| Overview of seizure types 
 
Self-limited epileptic seizures 
 I. Generalized onset 
  A. Seizures with tonic and/or clonic manifestations 
   1. Tonic-clonic seizures 
   2. Clonic seizures 
   3. Tonic seizures 
  B. Absences 
   1. Typical absnces 
   2. Atypical absences 
   3. Myoclonic absences 
  C. Myoclonic seizure types 
   1. Myoclonic seizures 
   2. Myoclonic astatic seizures 
   3. Eyelid myoclonia  
  D. Epileptic spasms 
  E. Atonic seizures 
 II. Focal onset (partial) 
  A. Local 
   1. Neocortical 
    a. Without local spread 
     i Focal clonic seizures 
     ii Focal myoclonic seizures 
     iii Inhibitory motor seizures 
     iv Focal sensory seizures with elementary symptoms 
     v Aphasic seizures 
    b. With local spread 
     i Jacksonian march seizures 
     ii Focal (asymmetrical) tonic seizures 
     iii Focal sensory seizures with experiential symptoms 
   2. Hippocampal and parahippocampal 
  B. With ipsilateral propagation to: 
   1. Neocortical areas (includes hemiclonic seizures) 
   2. Limbic areas (includes gelastic seizures) 
  C. With contralateral spread to: 
   1. Neocortical areas (hyperkinetic seizures) 
   2. Limbic areas (dyscognitive seizures with or without automatisms [psychomotor]) 
  D. Secondarily generalized 
   1. Tonic-clonic seizures 
   2. Absence seizures 
   3. Epileptic spasms (unverified) 
 III. Neonatal seizures 
 
Table continued on page 105. Modified from Engel et al., 2006. 
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TABLE 6-1| Overview of seizure types (continued) 
Status epilepticus 
I. Epilepsia partialis continua (EPC) 
 A. As occurs with Rasmussen syndrome 
 B. As occurs with focal lesions 
 C. As a component of inborn errors of metabolism 
  II. Supplementary motor area (SMA) status epilepticus 
  III. Aura continua 
  IV. Dyscognitive focal (psychomotor, complex partial) 
  status epilepticus 
 A. Mesial temporal 
 B. Neocortical 
V. Tonic-clonic status epilepticus 
VI. Absence status epilepticus 
 A. Typical and atypical absence status epilepticus 
 B. Myoclonic absence status epilepticus 
VII. Myoclonic status epilepticus 
VIII. Tonic status epilepticus 
IX. Subtle status epilepticus 
 
Modified from Engel et al., 2006. 
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6.2 Genomic regions excluded from PCA 
 
Table 6-2 | Genomic regions excluded from PCA 
Chr. region Start bp End bp 
1p33-p32.3 48,277,980 52,297,979 
2p11.2-q11.2 86,078,342 101,051,482 
2q21.2-q22.1 134,656,268 138,176,268 
2q32.1-q32.2 183,164,494 190,184,494 
3p21.31 47,514,996 50,034,996 
3p12.2-p12.1 83,407,310 86,927,310 
3p11.2-q11.2 88,907,310 96,027,310 
3q29 195,387,785 197,396,290 
5p12-q11.2 43,954,243 51,474,243 
5q21.1 97,962,100 100,482,101 
5q23.3-q31.1 128,962,101 131,982,101 
5q31.2 135,462,101 138,482,101 
6p22.2-p21.32 24,882,021 33,402,022 
6p12.1-q12 56,882,041 63,952,041 
6q24.1 139,948,307 14,246,8307 
7p11.2-q11.22a 55,215,791 66,565,850 
8p23.1 7,178,552 12,452,658 
8p11.21-q11.21 42,870,843 49,847,447 
8q23.2-q23.3 111,920,824 114,940,824 
10p11.21-q11.21 36,949,994 43,689,994 
11p11.2-q12.1 45,033,424 57,253,424 
11q14.2-q14.3 87,850,352 90,870,352 
12p11.21-q12 33,098,733 41,723,733 
12q24.11-q24.13 111,027,280 113,547,280 
15q13.2-q13.3 30,726,915 32,825,174 
15q24.1-q24.2 74,354,360 75,579,130 
17q12 34,804,328 36,329,039 
17q21.31-q21.32 43,534,138 44,643,937 
20q11.22-q11.23 32,526,339 35,076,586 
Known regions with high long range LD excluded from PCA, collectively from Fellay et al., 2007; Price et al., 
2008; Deng et al., 2008; Antonacci et al., 2009; Kasperaviciūte et al., 2010. Modified from 
[Molekulargenetische Exploration der idiopathisch generalisierten Epilepsien], Leu 2012. Physical positions 
in NCBI built 37.7, hg19. 
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6.3 QQ-plots of genome-wide associations studies 
6.3.1 QQ-plots of GWAS in GGE 
 
Figure 6-1 | QQ-plots of GWAS in GGE: A) LMM, 1,523 GGE cases vs. 2,454 controls; B) TDT, 566 GGE trios; 
C) Genome-wide meta-analysis of GGE. 
 
 
A B 
C 
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6.3.2 QQ-plots of GWAS in GAE 
 
Figure 6-2 | QQ-plots of GWAS in GAE: A) LMM, 705 GGE cases vs. 2,454 controls; B) TDT, 317 GAE trios; 
C) Genome-wide meta-analysis of GGE. 
 
 
A B 
C 
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6.3.3 QQ-plots of GWAS in JME 
 
  
Figure 6-3 | QQ-plots of GWAS in JME: A) LMM, 579 JME cases vs. 2,454 controls; B) TDT, 157 JME trios; C) 
Genome-wide meta-analysis of GGE. 
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6.4 Samples with recurrent microdeletions 
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6.5 Samples with exon-ablating microdeletions in NRXN1 and 
RBFOX1 
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